PF-07265803
Protocol C4411010
Final  Protocol, 26-January -2022
PFIZER CONFIDENTIAL
Page 1
Title Page
A PHASE 1, OPEN -LABEL, SINGLE -PERIOD , NON- RANDOMIZED STU DY TO 
EVALUATE THE PHARMAC OKINETICS, EXCRETION , MASS BALANCE AND 
METABOLISM OF [14C]PF -07265803 ADMIN ISTERED ORALLY TO HEA LTHY 
ADULT MALE PARTICIPANTS
Study Intervention Number : PF-
07265803
Study Intervention Name: N/A
USIND Number: 118,[ADDRESS_496223] Number: N/A
ClinicalTrials.gov ID:  TBD
Protocol Number: C4411010
Phase: 1
Brief Title: A Phase 1 Radiolabel Pharmacokinetics, Excretion, Mass Balance and Metabolism 
Study of [14C]PF -
07265803 .
This document and accompanying materials contain confidential information belonging to [COMPANY_007]. Except as 
otherwise agreed to in writing, by [CONTACT_185586] s, you agree to hold this information in 
confidence and not copy or disclose it to others (except where required by [CONTACT_1289] ) or use it for 
unauthorized purposes. In the event of any actual or suspected breach of this obligation, [COMPANY_007] must be 
prom ptly notified.

PF-[ADDRESS_496224] OF TABLES ................................ ................................ ................................ ..................... 8
1. PROTOCOL  SUMMARY .....................................................................................................9
1.1. Sy nopsis ....................................................................................................................9
1.2. Schema ....................................................................................................................10
1.3. Schedule of Activities .............................................................................................11
2. INTRODUCTION ...............................................................................................................14
2.1. Study  Rationa le.......................................................................................................14
2.2. Background .............................................................................................................14
2.2.1. Nonclinical Studies with PF -
07265803......................................................14
2.2.2. Nonclinical Pharmacology ..........................................................................15
2.2.3. Nonclinical Pharmacokinetics and Metabolism .........................................15
2.2.4. Nonclinical Safet y
......................................................................................16
2.2.5. Clinical Overview .......................................................................................16
2.3. Benefit/Risk Assessment
.........................................................................................17
2.3.1. Risk Assessment
.........................................................................................18
2.3.2. Benefit Assessment .....................................................................................19
2.3.3. Overall Benefit/Risk Conclusion ................................................................19
3. OBJECTI
VES AND EN DPOINTS .....................................................................................19
4. STUDY DESIGN .................................................................................................................19
4.1. Overall Design .........................................................................................................19
4.2. Scientifi c Rationale for Study  Design .....................................................................20
4.2.1. Choice of Contraception/Barrier Requirements .........................................20
4.2.2. Collection of Retained Research Samples ................................ .................. 21
4.3. Justification for Dose ..............................................................................................21
4.3.1. Dosimetry  Calculations ..............................................................................21
4.4. End of Study  Definition ..........................................................................................22
5. STUDY POPUL ATION
................................ ................................ ................................ ......22
5.1. I nclusion Criteria.....................................................................................................22
Age and Sex:
.........................................................................................................22
Type of Participant and Disease Characteristics: .................................................22

PF-07265803
Protocol C4411010
Final  Protocol, 26-January -2022
PFIZER CONFIDENTIAL
Page 4Weight: .................................................................................................................23
Informed Consent: ................................................................................................23
5.2. Exclusion Criteria ....................................................................................................23
Medical Conditions: ..............................................................................................23
Prior/Concomitant Therapy :
.................................................................................23
Prior/ Concurrent Clinical Study  Experience: .......................................................24
Diagnostic Assessments: ......................................................................................24
Other Exclusions: ..................................................................................................24
5.3. L ifesty le Considerations ..........................................................................................25
5.3.1. Meals and Dietary  Restrictions ...................................................................25
5.3.2. Caffeine, Alcohol, and Tobacco .................................................................26
5.3.3. Activity .......................................................................................................26
5.3.4. Contraception ..............................................................................................26
5.4. Screen Failures ........................................................................................................27
6. STUDY INT
ERVENTION(S) AND CONCOMITANT THERAPY .................................27
6.1. Study  Intervention(s) Administered ........................................................................27
6.1.1. Administration ............................................................................................27
6.2. Preparation, Handling, Storage, and Accountability ...............................................27
6.2.1. Preparation and Dispensing ........................................................................28
6.3. Measures to Minimize Bias: Randomization and Blinding .....................................29
6.3.1. Allocation to Study Intervention ................................................................29
6.4. Study  Intervention Compliance ...............................................................................29
6.5. Dose Modification ...................................................................................................29
6.6. Continued Access to Study  Intervention After the End of the Study ......................29
6.7. Treatment of Overdose
............................................................................................29
6.8. Concomitant Therapy ................................ ................................ .............................. 30
6.8.1. Rescue Medicine .........................................................................................30
7. DI SCONTINUATION O F STUDY 
INTERVENTION AND PARTI CIPANT 
DISCONTINUATION/WI THDRAWAL ...........................................................................31
7.1. D iscontinuation of Study  Intervention ....................................................................31
7.1.1. Potential Cases of Acute Kidney  Injury .....................................................31
7.2. Participant Discontinuation/Withdrawal From the Study ................................ .......[ADDRESS_496225] to Follow up
....................................................................................................32
8. STUDY ASSESSMENTS AND PRO
CEDURES...............................................................33
8.1. Efficacy  Assessments ..............................................................................................34
8.2. Safet y Assessments .................................................................................................34
8.2.1. Phy sical Examinations ................................................................................34
8.2.2. Vital Signs ..................................................................................................35
8.2.3. Ele
ctrocardiograms .....................................................................................35
8.2.4. Clinical Safety  Laboratory  Assessments ....................................................36
8.2.5. COVID -19 specific assessments .................................................................37
8.3. Adverse Events, Serious Adverse Events, and Other Safet y Reporting .................37
8.3.1. Time Period and Frequency  for Collecting AE and SAE Information .......37
[IP_ADDRESS]. Reporting S AEs to [COMPANY_007] Safety ...............................................38
[IP_ADDRESS]. Recording Nonserious AEs and SAEs on the CRF
...................38
8.3.2. Method of Detecting AEs and SAEs ..........................................................38
8.3.3. Follow -Up of AEs and SAEs ......................................................................38
8.3.4. Regulatory
 Reporting Requirements for SAEs ...........................................39
8.3.5. Environmental Exposure, Exposure During Pregnancy  or 
Breastfeeding, and O ccupational Exposure .....................................................39
[IP_ADDRESS]. Exposure During Pregnancy ......................................................39
[IP_ADDRESS]. Exposure During Breastfeeding ................................................41
[IP_ADDRESS]. Occupational Exposure .............................................................41
8.3.6. Cardiovascular and Death Events ...............................................................41
8.3.7. Disease -Related Events and/or Disease -
Related Outcomes Not 
Qualifying as AEs or SAEs ..............................................................................[ADDRESS_496226]
.............................................................42
[IP_ADDRESS]. Lack of Efficacy ........................................................................42
8.3.9. M edical Device Deficiencies ......................................................................42
[IP_ADDRESS]. Medication Errors ......................................................................42
8.4. Pharmacokinetics ....................................................................................................43
8.4.1. Plasma Analy sis of Non
-Radiolabeled PF -07265803 ................................43
8.4.2. Metabolite Profiling/ID ................................ ................................ .............. 44

PF-07265803
Protocol C4411010
Final  Protocol, 26-January -2022
PFIZER CONFIDENTIAL
Page [IP_ADDRESS]. Plasma for Metabolite Profiling/ID ...........................................44
[IP_ADDRESS]. Urine for Metabolite Profiling/ID
.............................................44
[IP_ADDRESS]. Feces for Metabolite Profiling/ID
.............................................44
8.4.3. Radioactivity ...............................................................................................45
[IP_ADDRESS]. Sample Collection .....................................................................45
[IP_ADDRESS]. P lasma/Blood Sample Collection for Total Radioactivity ........45
[IP_ADDRESS]. Urine Sample Collection for Total Radioactivity .....................45
[IP_ADDRESS]. Fecal Sample Collection for Total Radioactivity ......................45
[IP_ADDRESS]. Emesis Sample Collection for Total Radioactivity ....................45
8.5. Genetics ...................................................................................................................46
8.5.1. Specified Genetics ......................................................................................46
8.5.2. Retained Research Samples for Genetics
...................................................46
8.6. Biomarkers ..............................................................................................................46
8.6.1. Specified Gene Expression (RNA) Research .............................................46
8.6.2. Specified Protein Research .........................................................................46
8.6.3. Specified Metabolomic Research ...............................................................46
8.7. I mmunogenicit y Assessments .................................................................................46
8.8. Health Economics ...................................................................................................46
9. STATI STICAL CONSI DERATIONS
................................................................................46
9.1. Statistical Hy potheses .............................................................................................47
9.2. A nalysis Sets ...........................................................................................................47
9.3. Statistical Analy ses.................................................................................................47
9.3.1. General Considerations ...............................................................................47
9.3.2. Primary  Endpoint(s) ................................ ................................ .................... 48
[IP_ADDRESS]. Metabolic Profiling/Identification .............................................48
9.3.3. Secondary  Endpoint(s) ................................................................................48
[IP_ADDRESS]. Pharmacokinetic Parameters .....................................................48
9.3.4. Other Safet y Analyses ................................................................................49
[IP_ADDRESS]. Electrocardiogram Analy ses......................................................50
[IP_ADDRESS]. Other Anal yses..........................................................................50
9.4. I nterim Anal yses.....................................................................................................50

PF-07265803
Protocol C4411010
Final  Protocol, 26-January -2022
PFIZER CONFIDENTIAL
Page 79.5. Sample Size Determination .....................................................................................50
10. SUPPORTING DOCUM ENTATION AND OPERATI ONAL 
CONSI DERATIONS
..........................................................................................................51
10.1. Appendix 1: Regulatory , Ethical, and Study  Oversight Considerations ...............51
10.1.1. Regulatory and Ethical Considerations ....................................................51
[IP_ADDRESS]. Reporting of Safety  Issues and Serious Breaches of the 
Protocol or I CH GCP .........................................................................51
10.1.2. Financial Disclosure .................................................................................52
10.1.3. I nformed Consent Process ........................................................................52
10.1.4. Data Protection .........................................................................................53
10.1.5. Committees Structure ...............................................................................53
[IP_ADDRESS]. Data Monitoring Committee ................................ ................... 53
10.1.6. Dissemination of Clinical Study  Data ......................................................53
10.1.7. Data Qualit y Assurance ............................................................................55
10.1.8. Source Documents ....................................................................................56
10.1.9. Study  and Site Start and Closure ..............................................................56
10.1.10. Publication Policy ...................................................................................57
10.1.11. Sponsor’s Qualified Medical P ersonnel
.................................................58
10.2. Appendix 2: Clinical Laboratory  Tests .................................................................59
10.3. Appendix 3: Adverse Events: Definitions and Procedures for Recording, 
Evaluating, Follow -Up, and Reporting .....................................................................60
10.3.1. Definition of AE .......................................................................................60
10.3.2. Definition of an SAE ................................................................................61
10.3.3. Recording/Reporting and Follow
-Up of AEs and/or SAEs During 
the Active Collection Period ............................................................................62
10.3.4. Reporting of SAEs
....................................................................................66
10.4. Appendix 4: Contraceptive and Barrier Guidance ................................ ................ 67
10.4.1. Male Participant Reproductive Inclusion Criteria ....................................67
10.4.2. Female Participant Reproductive Inclusion Criteria .................................67
10.4.3. Woman of Childbearing Potential ................................ ............................ 67
10.4.4. Contraception Methods ................................ ................................ ............. 68
10.5. Appendix 5: Genetics ............................................................................................70
10.6. Appendix 6: L iver Safety : Suggested Actions and Follow -Up Assessments .......71

PF-07265803
Protocol C4411010
Final  Protocol, 26-January -2022
PFIZER CONFIDENTIAL
Page 810.7. Appendix 7: ECG Findings of Potential Clinical Concern ...................................73
10.8. Appendix 8: 
Prohibit ed Concomitant Medications That May Result in DDI .......75
10.9. Appendix 9: Abbreviations
...................................................................................[ADDRESS_496227] OF TABLES
Table 1. Blood Sampling Volume ..........................................................................34
Table 2. Analy sis Sets .............................................................................................47
Table 3. Pharmacokinetic Parameters .....................................................................49
Table 4. Protocol -Required Safet y Laboratory  Assessments .................................59

PF-07265803
Protocol C4411010
Final  Protocol, 26-January -2022
PFIZER CONFIDENTIAL
Page 91.PROTOCOL SUMMARY 
1.1.Synopsis 
Brief Title
A Phase 1 Radiolabel Pharmacokinetics, Excretion, Mass Balance and Metabolism Study  of 
[14C]PF -07265803.
Rationale
The purpose of this Phase 1 study  is to assess the pharmacokinetics, excretion, mass balance 
and metabolism of PF-072658 03 (formerl y known as known as ARRY - 371797) in healthy  
adult male participant s.Only  males will be included in this study  given the use of 
radiolabeled substance and the desire to enroll a homogeneous population given the small 
sample size of this study .
Administration of the investigational product, [14C]PF -[ADDRESS_496228] the intended route of administration in the treatment of lamin A/C gene 
mutation ( LMNA) -related DCM. PF -07265803 will be administered as an extemporaneously  
prepared liquid formulation in this study . In order to limit the confounding of absorption, 
[14C]PF -[ADDRESS_496229] 10 hours .
Objectives and Endpoints
Objectives Endpoints
Prim ary: Prim ary: 
To characterize rateandextent ofexcretion oftotal
radioactivity inurine andfeces, following a single
oraldose of [14C]PF-07265803 administered to
healthy adult maleparticipant s.Mass Balance: cumulative recovery of urinary, 
fecal, and total excretion of radioactivity over time 
expressed as percentage of total radioactive dose 
administered.
To characterize metabolic profile and identify 
circulating and excreted metabolites following 
administration of a single oral dose of [14C]PF -
07265803 to healthy adult male participants.Metabolic p rofiling/identification and determination 
of relative abundance of PF -0726580 3and t he 
metabolites of PF -0726580 3in plasma, urine, and 
feces.
Secondary: Secondary: 
To quantify plasma concentrations and 
pharmacokinetic parameters of PF -07265803 ,its 
known circulating metabolites ( PF-07327859 , PF-
07327860 , PF-07327890) and total radioactivity in 
plasma following administration of a single oral 
dose of [14C]PF -[ADDRESS_496230],AUC inf, CL/F , 
Vz/F, Cmax, Tmax, and t½to describe single dose PK 
of:PF-07265803 and where a ppropriate PF-
07327859 , PF-07327860, PF -07327890.
Total radioactivity in plasma; PF -07265803 ,PF-
07327859 , PF-07327860 and PF -07327890
concentrations in plasma.
To evaluate safety and tolerability of a single oral 
dose of [14C]PF-07265803 administered to healthy 
adult male participant s.Safety endpoints including physical examinations, 
adverse events, clinical laboratory measurements, 
vital signs and ECG.

PF-07265803
Protocol C4411010
Final  Protocol, 26-January -2022
PFIZER CONFIDENTIAL
Page 10Overall Design
This is a Phase 1, open- label, single -period , single -center, non -randomized study  in health y 
adult male participants .
Brief Summary
In this study , mass balance and metabolism of 400 mg PF-07265803 containing 100 µCi 
[14C]PF -07265803 will be assessed.  Health y participant s will be screened up to 28 day s prior 
to dosing to determine eligibility . 
Number of Participants
Approximately  6participants will be enrolled to study  intervention .
Note: "Enrolled" means a participant's, or his or her legally  authorized representative ’s, 
agreement to participate in a clinical study following completion of the informed consent 
process and screening . A participant will be considered enrolled if the informed consent is 
not withdrawn prior to participating in an y stud y activity  after scree ning.  Potential 
participants who are screened for the purpose of determining eligibility  for the study , but do 
not participate in the study, are not considered enrolled, unless otherwise specified b y the 
protocol.
Intervention Groups and Duration
The dura tion of this non -randomized Phase 1, open
-label, single -center, single -dose study  is 
approximately  7 day s, with a 30- day safet y follow up . The maximum period of confinement 
is expected to be 14 day s. The minimum period of confinement is expected to be 3 day s .  
Data Monitoring Committee or Other Independent Oversight Committe e: No
This study  will not use a DMC or IOC.
Statistical Methods
There will be no formal hy pothesis testing in this study . The sample size of [ADDRESS_496231] 4 participant s provide evaluable data; with intent not to 
replace participant s who prematurel y withdraw (or offer non- evaluable or partially  evaluable 
data).
1.2.Schema
Not applicable .

PF-07265803
Protocol C4411010
Final  Protocol, 26-January -2022
PFIZER CONFIDENTIAL
Page 111.3. S chedule of Activ ities
The SoA table provides an overview of the protocol visits and procedures. Refer to the STUDY ASSESSMENTS AND 
PROCEDURES section of the protocol for detailed information on each procedure and assessment required for compliance with the 
protocol. 
The investigator may  sche dule visits (unplanned visits) in additi on to those listed in the SoA table , in order to conduct evaluations or 
assessments required to protect the well -being of the participant .
Visit Identifier
Abbreviations used in this t able may 
be found in 10.9.Screening Period 1 Follow -Up Early Termination/
Discontinuation
Days Relative to Day 1 Day -28 to 
Day -2Day -1 Day 1 Day 
2Day
3Day 
4Day 
5Day
6-1428-35 Daysb
Informed consent X
CRU confinementaX X X X X X Xa
Inclusion/exclusion criteria X X
Medical/medication history X X
Physical exambX XcX
Safety laboratoryiX X XcX
Demography X
Height and Weight X
Urine drug /alcohol/co tininetestingkX X
12-Lead EC G X Xg,jXcX
Blood pressure and pulse rate X Xh,jXcX
Contraception check X
HIV, HBsAg, HCVAb X
COVID -[ADDRESS_496232] MealseX X X X X X X
Spot Collection for Urinalysis (and
Microscopy, if needed)X X XcX
Retained Research Sample for 
Genetics (Prep D1)fX
CRU discharge Xa
Serious and nonserious AE
monitoringX X X X X X X X X X

PF-07265803
Protocol C4411010
Final  Protocol, 26-January -2022
PFIZER CONFIDENTIAL
Page 12Visit Identifier
Abbreviations used in this t able may 
be found in 10.9.Screening Period 1 Follow -Up Early Termination/
Discontinuation
Days Relative to Day [ADDRESS_496233] be extended until >90% radioactive dose administered has been recovered or<1% is excreted in total (urine and feces) in any 24H period for two 
consecutive days . Maximum confinement will be 14 days.
b.Complete physical examination will be conducted at Day -1 (Period 1); otherwise brief physical exam envisioned for findings during previous PE or new/open AEs, at 
Investigator discretion. Follow -up over the phone may be conducted if no new/open AE’s at Investigators discretion .
c.Procedures to be completed at time of discharge (approximately [ADDRESS_496234] dose )only, with clinical laboratory tests conducted only after criteria for discharge 
(footnote “a”) are satisfied
d.Assessments for COVID -[ADDRESS_496235] 15 g of fiber per 1000 kcal or f iber 
capsules containing the equivalent amount of fiber may be administered daily (beginning at least 8 hr after dosing ).
f.Prep D1 Retained Research Samples for Genetics: If not collected on the designated collection day, collect at the next available time point when biospecimens are being 
collected in conjunction with a participant visit. Sample should be collected prior to dose.
g.ECG assessment will occur prior to dosing (approximately 1 hour) .
h.Pre-dose vital sign measurements. Predose (approximately 1 hour) vital sign measurements on Day 1 .
i.Safety laboratories consistent with those described in Section 10.2
j.ECG and vital signs assessment for eligibility may be considered at both screening and Day 1 visit (predose).
k.Urine drug screen andcotinine conducted at screening andcheck -in, and urine alco hol conducted at check -inonly.

PF-07265803
Protocol C4411010
Final  Protocol, 26-January -2022
PFIZER CONFIDENTIAL
Page 13Visit Identifier Period 1
Study Day1 2 3 4 5 6 Early Termination/
Discont inuation
Hours Before/After Dose 0a0.5 1 2 3 4 6 9 12 24 36 48 72 96 120
Study intervention administration X
PK blood sampling X X X X X X X X X X X X X X X X
Radioactivity and metabolite ID in blood  X X X X X X X X X X X X X X X X
Interval collection for radioactivity and metabolite ID 
in urinebX      X X X  X X X X
Interval collection for radioactivity and metabolite ID 
in fecescX        X X  X X X X
Emesis Collection for Radioactivity Measurement, if 
OccursX         X  
a. Predose sample collection
b. “Blank” spot urine sample to be collected anytime predose (Day 1)andpostdose in intervals of 0-6H , 6-12H, 12-24H, 24-48H, 48-72H, 72-96H, and each subsequent 24H 
interval up to discharge.
c. “Blank” fecal sample to be collected prior to dosing butpost admission to CRU andin intervals of each 24H period post dose up to discharge

PF-07265803
Protocol C4411010
Final  Protocol, 26-January -2022
PFIZER CONFIDENTIAL
Page 142.INTRODUCTION
PF-07265803 (formerl y known as known as ARRY-371797) is a potent and selective, oral 
small molecule inhibitor of the α isoform of p38 MAPK. Mutations in the LMNA gene 
encoding nuclear lamina components cause nuclear envelope d ysfunction leading to altered 
nuclear activity , impaired structural dy namics and aberrant cell signaling including activation 
of p38α MAPK signaling pathway s.  Structural alterations in the n uclear envelope and 
connected cy toskeleton resulting from  LMNA  mutations make cardiomy ocytes highl y 
susceptible to damage even by  [CONTACT_394981], leading to a disease specific 
maladaptive activation of the p38α MAPK. Up-regulation of p38 M APK has been observed 
in the hearts of animal models and adult patients with 
LMNA -related DCM compared to wild -
type/healthy  individuals. Inhibition of p38 MAPK in this disease setting may  halt aberrant 
apoptosis and cardiac remodeling resulting in improved cardiac function.
2.1.Study Rationale 
The purpose of this Phase 1 study  is to assess the pharmacokinetic s, excretion , mass balance
and metabolism of PF -07265803 (formerl y known as ARRY -[ZIP_CODE]) in healthy  adult male 
participant s. Onl y males will be included in this study  given the use of radiolabeled 
substance and the desire to enroll a homogeneous population given the small sample size of 
this study .
Administration of the investigational product, [14C]PF -[ADDRESS_496236] the intended route of administration in the treatment of lamin A/C gene 
mutation ( LMNA) -related DCM. PF -07265803 will be administered as an extemporaneously  
prepared liquid formulation in this study . In order to limit the confounding of absorption,
[14C]PF -[ADDRESS_496237] 10 hours.
2.2.Background 
In the completed Phase 2 study  ARRAY -797- 231, treatment with PF -07265803 resulted in 
rapid (<4 weeks), sustained increases in functional capacity  in partic ipants with 
LMNA -
related DCM. Improvements on the 6MWT compared to baseline, the primary  endpoint, 
were mirrored b y favorable changes in NT -proBNP levels, L VEF, and RV fractional area. 
PF-[ADDRESS_496238] with its intended target, p38 MAPK. I n enzy me studies, PF-
07265803 inhibits p38a with a half -maximal inhibitory  concentration ( IC50) of 8.[ADDRESS_496239] demonstrated that p38 MAPK is activated in murine models 
of LMNA -related DCM and that this activation of p38 MAPK precedes the development of 
cardiac d ysfunction. PF -07265803 has been tested in the homozy gous LMNA H222P model 
of EDMD with cardiomyopathy  (EDMD2, MIM:181350) and in the homozygous LMNA 
N195K model of LMNA -related DCM, one of the original LMNA mutations linked to familial 
DCM with conduction defects1.These 2 nonclinical models bracket the spectrum of 
phenoty pes (EDMD2: cardiac and skeletal muscle disease and DCM: cardiac disease only ). 
Results from these studies confirm that treatment with PF- 07265803 improves cardiac 
structure and function and reduces m yocardial apoptos is. 
2.2.3. Nonclinical Pharmacokinetics and Metabolism
Multiple Phase 1 enzy mes (CYPs, FMOs, amidases, and esterases) are involved in the 
metabolism of PF -07265803.
In vitro experiments indicated that PF-[ADDRESS_496240] to hepatic metabolism. The principal metabolite in vivo, 
AR00420643, is formed in in vitro incubations with liver microsomes, hepatocy tes, plasma, 
or blood.
CYP -
mediated metabolism was primarily  by [CONTACT_097]3A4 and CYP2D6; however, the se 
enzy mes do not generate the principal metabolite in vivo. I n vivo, other Phase 1 enzy mes 
(FMOs, amidases, and esterases) are involved in the metabolism of PF -07265803, with the 
major mechanism of clearance thought to be through an unidentified h ydrolase enzy me. PF -
07265803 and its metabolites were weak inhibitors of 5 major CYP isoforms in vitro 
(CYP2C19, CYP2C9, CYP1A2, CYP2D6, CYP3A4. PF- 07265803 is a weak time - dependent 
inhibitor of CYP3A4. I n in vitro studies in human hepatocytes, PF -07265803 and its
metabolites are inducers of CYP3A, while only  metabolites AR00420643 and AR00428028 
induce CYP2B6.  Based on potential for mixed induction/inhibition of CYP3A4, the net 
effect of PF -[ADDRESS_496241] indicated that PF -07265803 was well-tolerated at 
multiple doses of up to 100 mg/kg BID in rats and monkey s, with GI side effects and 
minimal clinical pathology  changes. Associated histopathology changes were r eversible in 
monkey s treated with doses of up to 100 mg/kg BID for [ADDRESS_496242] to severit y and 
incidence at the 100 mg/kg BID (200 mg/kg/day ) dose level. In the chronic dosing studies for 
up to 6 months in the rat and 9 months in the monkey  at doses up to 30 mg/kg BID, there 
were no significant adverse histopathology  findings. I n general, administration of PF -
07265803 at doses of up to 30 mg/kg BID was tole rated in- life in rats and monkey s in 
chronic safet y studies. Administration of PF- 07265803 to rats for up to 3 months was 
associated with microscopic findings of skeletal muscle fiber changes, with no effects on 
clinical chemistry . These skeletal muscle ch anges were reversible after dosing cessation and 
with continued dosing for up to 6 months. Evidence of gastric irritation and increased gastric 
fluid secretion was observed in rats after a single oral dose of 100 mg/kg of PF -07265803. 
After treatment with PF-[ADDRESS_496243] dose groups, these GI 
effects resolved within 28 day s after discontinuation of treatment with PF -07265803.
2.2.5. Clinical Overview
PF-07265803 is currently undergoing investigation in a Phase 3, multinational, randomized, 
placebo controlled stud y in which patients with symptomatic LMNA -related DCM (planned 
N=160) are randomized 1:1 to receive PF- 07265803 400 mg BID or placebo.
PF-07265803 has been investigated in 12completed clinical studies including a Phase 2 
study  in patients with 
LMNA -related DCM andlong-term rollover extension to the Phase 2 .
In addition, 5 studies ( onePhase 1b and four Phase 2) in patients with painful inflammatory  
conditions have been completed as well as five Phase 1 studies in healthy  subjects.
In 5 clinical studies in healthy  subjects, PF -07265803 demonstrated an accepta ble safet y 
profile when administered at single doses up to 900 mg QD, up to 400 mg/day  for 14 day s 
and up to 2000 mg/day  for [ADDRESS_496244] commonly reported AEs in 
subjects receiving PF -07265803 were dizziness, headache, diarrhea, naus ea and acne; the 
incidence of these AEs was not clearl y related to the PF -07265803 dose or to the duration of 
exposure.
Detailed information regarding clinical studies of PF-07265803 is presented in the IB.

PF-07265803
Protocol C4411010
Final  Protocol, 26-January -2022
PFIZER CONFIDENTIAL
Page 172.3.Benefit/Risk Assessment
PF-07265803 as a single dose is not expected to provide an y clinical benefit to healthy 
participants. This study  is designed primaril y to generate safety, tolerability, and 
pharmacokinetic data for further clinical development.
More detailed information about the known and expecte d benefits and risks and reasonabl y 
expected adverse events of PF-07265803 may be found in the Investigator’s B rochure , which 
is the SRSD for this study . 

PF-07265803
Protocol C4411010
Final  Protocol, 26-January -2022
PFIZER CONFIDENTIAL
Page 182.3.1. Risk Assessment
Potential Risk of Clin ical Significance Summary of Data/Rationale for Risk Mitigation Strategy
Study Intervention(s) PF-0726580 3
An identified risk associated with this study 
intervention is stomatitis. It is a common ( ≥1/100 to 
<1/10) event in the protocol population.The potential risks are based on adverse events 
reported in early studies of PF-0726580 3 (ARRY -
371797 ).AEs will be monitored on an ongoing basis. 
Instructions for managing potential cases of 
stomatitis can be discussed with the sponsor .
First time clinical administration of [14C]PF -
07265803Single oral doses upto900mgofPF-
07265803 observed tobewell tolerated;
single, oraldose ofPF-07265803 inthisstudy
(400mg) represents is>2-foldlower
The maximum whole -body exposure of 
humans to radioactivity from a 100 μCi (3.7
MBq) PO dose of [14C]PF-07265803 PF-
0726580 3, which w as predicted using this 
rodent tissue distribution data was0.39 mrem .
This w as approximately 0.013% of the 3 to 5 
rem limit specified for whole -body exposure 
by [CONTACT_281934]. The 
predicted exposure of the blood -forming
organs, gonads and 29 other tissues to 
radioactivity from an PO dose of 100 μCi of 
[14C]PF -07265803 to humans were each less 
than 1.0% of the 3 to 5 rem limits specified 
by [CONTACT_281934].Administration ofPF-0726580 3willoccur in
aninpatient setting under close supervision
Clear communication viaICD ofnegligible
riskwith the[14C]PF -07265803 doses
administered relative topreviously
administered oraldoses .

PF-07265803
Protocol C4411010
Final  Protocol, 26-January -2022
PFIZER CONFIDENTIAL
Page 192.3.2. Benefit Assessment
The participants in this study  are not expected to obtain any  specific benefit bey ond 
contributing to the process of developi[INVESTIGATOR_336243]. They  will 
receive close monitoring of their safety  via study  procedures undertaken (eg. Phy sical 
examination , 12-lead ECGs, vital signs) which will occur as outlined in this protocol.
2.3.3.
Overall Benefit /Risk Conclusion
Taking into account the measures to minimize risk to study participants , the potential risks 
identified in association with PF-07265803 are justified by  [CONTACT_394982] -related DCM .The overall benefit:risk profile for PF -
[ADDRESS_496245] of this study .
3.OBJECTIVES AND ENDPO INTS
4.STUDY DESIGN
4.1.Overall Design
This is a Phase 1, open -label, single -period, single -center, non -randomized single oral dose 
study  administering a liquid formulation with 400mg of PF - 0726580 3containing 100 µCi of 
[14C]PF -07265803 to healthy  male participants .Participant swill be screened for p articipation 
in this study  within 28 day s before dosing on Day  1 to confirm that they  meet the 
inclusion/exclusion criteria specified in Section 5.1 .Objectives Endpoints
Prim ary: Prim ary: 
To characterize rateandextent ofexcretion oftotal
radioactivity inurine andfeces, following a single
oraldose of [14C]PF -07265803 administered to
healthy adult maleparticipant s.Mass Balance: cumulative recovery of urinary, 
fecal, and total excretion of radioactivity over time 
expressed as percentage of total radioactive dose 
administ ered.
To characterize metabolic profile and identify 
circulating and excreted metabolites following 
administration of a single oral dose of [14C]PF -
07265803 to healthy adult male participants.Metabolic p rofiling/identification and determination 
of relati ve abundance of PF -0726580 3 and the 
metabolites of PF -0726580 3in plasma, urine, and 
feces.
Secondary: Secondary: 
To quantify plasma concentrations and 
pharmacokinetic parameters of PF -07265803 ,its 
known circulating metabolites ( PF-07327859 , PF-
07327860, PF -07327890) and total radioactivity in 
plasma following administration of a single oral 
dose of [14C]PF -[ADDRESS_496246],AUC inf, CL/F, 
Vz/F, C max, Tmax, and t½to describe single dose PK 
of: PF -07265803 and where appropriate PF-
07327859 , PF-07327860, PF -07327890.
Total radioactivity in plasma; PF -07265803 ,PF-
07327859 , PF-07327860 and PF -07327890 
concentrations in plasma.
To evaluate safety and tolerability of a single oral 
dose of [14C]PF -[ADDRESS_496247] be extended until >90% radioactive dose administered has been recovered 
or<1% is excreted in total (urine and feces) in any  24H period for two consecutive day s. 
Maximum confinement will be [ADDRESS_496248] 
will be approximately  5 weeks (minimum) to 8 weeks (maximum). Approximately  [ADDRESS_496249] participant swho are 
prematurel y withdrawn.
4.2.Scientific Rationale for Study Design
This study  will investigate the ADME of [14C]PF -07265803 and characterize plasma, fecal
and urinary  radioactivit y and identify  any metabolites of [14C]PF -
[ADDRESS_496250] on 
metabolism by  [CONTACT_74639]. Oral dosing will be administered in the absence of food , as food has 
been shown to potentiall ydecrease exposures of PF -07265803 and mimics how P F -
07265803 is being administered in the clinical program. Female subjects will be excluded to 
align with regulatory  guidance. The ‘as low as (is) reasonabl y achievable’ (ALARA) 
principle prescribed b y the FDA recommends that radiation exposure to subjects should be 
kept ALARA; therefore, if no specific reason exists to include females (ie, no available data 
suggest metabolism of the PF-07265803 is different in females versus males), then the 
radiation exposure to female subjects should ideally  be kept at ze ro by [CONTACT_394983].
The potential risk of exposure to PF
-07265803 in a sexual partner of a male participant in 
this study  via ejaculate is possible, and therefore contraceptio n (condom) use in male 
participants is warranted. The embry o-fetal developmental toxicity  studies support the 
exclusion of pregnant women from clinical studies of PF -
07265803 and the continued 
consideration that partners of study  participants who are WOCBP use appropriate 
contraception in addition to condom use.
Banked Biospecimens will be collected and stored for further anal yses which may , for 
example, provide greater understanding of the study  intervention.
4.2.1. Choice of Contraception/Barrier Requirements 
Nonclinical studies suggest risk for severe manifestations of developmental toxicity  at 
relevant clinical exposures for PF-07265803. Therefore, the use of a highly  effective method 
of contraception is required (see Appendix 4 ).

PF-[ADDRESS_496251]  inhibition (cy tokines, CRP) of greater than 80% 
(Study  ARRAY -797- 101). In a clinical study  of pain relief (Stud y ARRAY 797 -221), [ADDRESS_496252] (associated with p38 MAPK inhibition), 
with 200 mg PF -07265803 providing significantly  less benefit.
Doses utilized in the nonclinical studies of LMNA -related DCM, where positive effects on 
cardiovascular function and survival were demo nstrated, provided exposure consistent with 
clinical exposure observed with 200 to 400 mg BID of PF -07265803. Study  ARRAY -797-
231 was a Phase 2, two -arm study  designed to investigate the efficacy  and safet y of 48 weeks 
of treatment with PF -07265803 in 12 s table participants with DCM secondary  toLMNA
mutations. I n this study , participants were alternately assigned to receive PF -07265803) at 
100 mg BID or 400 mg BID resulting in n = 6 per dose group. Participants in the 100 mg 
BID dose group were allowed to dose escalate to 400 mg BID after 24 weeks of treatment. 
Three participants dose escalated to 400 mg BID after their Week 24 visits and all 3 
remained at the 400 mg BID dose through Week 48. In this study  PF-07265803 was 
generall y well tolerated; most AEs were mild and only  1 participant discontinued due to a 
study  intervention -related AE. There was also an apparent trend towards a dose response 
with greater efficacy  observed with the 400 mg BID dose. Finally , the 400 mg BID dose of 
ARRY -371797 ( PF-07265803 )appeared to be associated with larger favorable changes in 
NT-proBNP concentration than the 100 mg BID dose in an anal ysis of aggregated mean 
change from baseline at all time points . 
4.3.1. Dosimetry Calculations
Dosimetry calculations for this proposed [14C]P
F-07265803 ADME study in healthy ,male
subjects are based on a tissue distribution study conducted with Sprague Dawley  and Long
Evans male rats receiving an oraldose of PF-07265803 .  Pharmacokinetic parameters and 
dosimetry projections were calculated forblood andtissues, including (but not limited to)
International Commission onRadiological Protection (ICRP) 30critical tissues of bones, 
bone marrow, lungs, testes (gonads), and thy roidand the four tissues with highest 
concentrations of radioactivity  in tissues including the gastrointestinal tract, liver, 
renal 
cortex ,andrenal medulla.
The maximum whole -body  exposure of humans to radioactivity  from a 100 μCi PO dose of 
[14C]PF -07265803 , which was predicted using this rodent tissue distribution data, was
0.[ZIP_CODE] rem. This was approximately  0.013% of the 3 to 5 rem limit specified for whole -
body exposure by  [CONTACT_281934]. The predicted exposure of the blood -

PF-07265803
Protocol C4411010
Final  Protocol, 26-January -2022
PFIZER CONFIDENTIAL
Page 22forming organs, gonads and 29 other tissues to radioactivity  from an PO dose of 100 μCi of 
[14C]PF -07265803 to humans were each less than 1.0% of the 3 to 5 rem limits specified by  
[CONTACT_281934].
The planned radioactive dose in the current study  is 100 µCi of [14C]PF-07265803; based on 
ICRP 30 weighting factors, this would result in an effective dose to the whole body  of 
0.39 mrem. T heplanned radioactive dose of approximately  100μCi of [14C]PF-[ADDRESS_496253] scheduled procedure shown in SoA (ie, follow -up phone call).
The end of the stud y is defined as the date of the last scheduled procedure shown in SoA for 
the last participant in the trial.
5.STUD Y POPULATION
This study  can fulfill its objectives only  if appropriate participant s are enrolled. The 
following eligibility  criteria are designed to select participant s for whom participation in the 
study  is considered appropriate. All relevant medical and nonmedical conditions should be 
taken into consideration when deciding whether a particular participant is suitable for this 
protocol .
Prospective approval of protocol deviations to recruitment and enrollment criteria ,also 
known as protocol waivers or e xemptions, is not permitted .
5.1.
Inclusion Criteria
Participants are eligible to be included in the study onl y if all of the following criteria appl y:
Age and Sex :
1. Participants must be male and ≥18 years of age at the time of signing the ICD .
Refer to Appendix 4forreproductive criteria for male (Section 10.4.1)
participant s.
Type of Participant and Disease Characteristics:
2.Male p
articipants who are overtl y health y as determined by [CONTACT_394984], phy sical examination, laboratory  tests, and ECG
monitoring .
3.Participants who are willing and able to compl y with all scheduled visits, treatment 
plan, laboratory  tests , lifesty le considerations , and other study  procedures.

PF-07265803
Protocol C4411010
Final  Protocol, 26-January -2022
PFIZER CONFIDENTIAL
Page 23Weight:
4.BMI of 18.0 to 32kg/m2; and a total bod y weight >50 kg (110 lb).
Informed Consent:
5.Capable of giving signed informed consent as described in Appendix 1 ,which 
includes compliance with the requirements and restrictions listed in the I CDand in 
this protocol.
5.2. Exclusion Criteria
Participants are excluded from the study  if any  of the following criteria apply :
Medical Conditions:
1.Evidence or history  of clinically  significant hematological, renal, endocrine, 
pulmonary , gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic al, or 
allergic disease (including drug allergies, but excluding untreate d, asymptomatic, 
seasonal allergies at the time of dosing ).
2.Any condition possibly  affecting drug absorption (eg, gastrectomy , cholecy stectom y, 
gastric b ypass, duodenotomy, colectomy, history of inflammatory bowel disease ).
3.History  of HIV infection, hepatitis B, or hepatitis C; positive testing for HIV, HBsAg, 
or HCVAb. Hepatitis B vaccination is allowed.
4.Participant s with a history  of irregular bowel movements; e.g., less than 1 bowel 
movement per day , regular epi[INVESTIGATOR_394977], irritable bowel 
syndrome (IBS) or lactose intolerance.
5.Other medical or psy chiatric condition including recent (within the past year) or 
active suicidal ideation /behavior or laboratory  abnormality  or other conditions or 
situations related to COVI D
-19 pandemic (eg. Contact [CONTACT_216478])] that may  
increase the risk of study participation or , in the investigator’s judgment, make the 
participant inappropriate for thestudy .
Prior/Concomitant Therapy:
6.Use of prescription or nonprescription drugs and dietary and herbal supplements 
within 7 days or 5 half-lives (whichever is longer) prior to the first dose of study  
intervention with theexception ofmoderate/potent CYP3A inducers which are
prohibited within [ADDRESS_496254] dose of stud y
intervention ..  (Refer to Section 6.8Concomitant Therap y for additional details ).
7.Current use of an y prohibited concomitant medication(s) or those unwilling/unable to 
use a permitted concomitant medication(s). Refer to S ection 6.8Concomitant 
Therap y.

PF-07265803
Protocol C4411010
Final  Protocol, 26-January -2022
PFIZER CONFIDENTIAL
Page 24Prior/ Concurrent Clinical Study Experience:
8.Previous administration with an investigational drug within 30 days (or as determined 
by [CONTACT_19970]) or 5half-lives preceding the first dose of study  intervention
used in this study (whichever is longer). 
Diagnostic Assessments:
9.A positive urine drug test .
10.Screening and baseline supi[INVESTIGATOR_30991] >140 mmHg (sy stolic) or >90mmHg (diastolic), 
following at least [ADDRESS_496255]. If BP is >140 mmHg (s ystolic) or 
>
90mmHg (diastolic), the BP should be repeated 2more times and th e average of 
the 3 BP values should be used to determine the participant ’s eligibility .
11.Screening and baseline standard 12- lead ECG thatdemonstrates clinically relevant 
abnormalities thatmay affect participant safety or interpretation of study results ( eg,
baseline QTc Finterval >[ADDRESS_496256] -degree AVblock, or serious brady arrhy thmias 
or tachy arrhy thmias). If the baseline uncorrected QT interval is >450 msec, this 
interval should be rate -
corrected using the Fridericia method and the resulting QTcF 
should be used for decision making and reporting. If QTc Fexceeds 450 msec, or 
QRS exceeds 120 msec , the ECG should be repeated 2 more times and the average of 
the 3 QTcFor QRS values should be used to determine the participant’s eligibility .
Computer -interpreted ECGs should be overread b y a physician experienced in 
reading ECGs before excludin g a participant.
12.Participant s with ANY of the following abnormalities in clinical laboratory  tests at 
screening, as assessed b y the study -specific laboratory  and confirmed b y a single 
repeat test, if deemed necessary : 
AST or ALT level ≥ 1.5 × ULN;
Total bilirubin level ≥1.5 × ULN; participants with a history of Gilbert's 
syndrome may  have direct bilirubin measured and would be eligible for this study  
provided the direct bilirubin level is≤ ULN.
Other Exclusions:
13.History  of alcohol abuse or binge drinking and/or any  other illicit drug use or 
dependence within 6 months of Screening. Binge drinking is defined as a pattern of 
5(male) or more alcoholic drinks in about 2 hours . As a general rule, alcohol intake 
should not exceed 14 units per week (1 unit=
8 ounces (240 mL) beer, 1 ounce 
(30mL) of 40% spi[INVESTIGATOR_107060] 3 ounces (90 mL) of wine).
14.Positive urine drug screen or cotinine at screening or check -in, and positive urine 
alcohol at check -in.

PF-07265803
Protocol C4411010
Final  Protocol, 26-January -2022
PFIZER CONFIDENTIAL
Page 2515.Blood donation (excluding plasma donations) of approximately  1pi[INVESTIGATOR_11731] (500 mL) or 
more within [ADDRESS_496257] of the 
study , site staff otherwise supervised by  [CONTACT_093], and their respective family  
members .
19.Subjects with exposure to significant diagnostic or therapeutic radiation (eg, serial 
x-ray, computed tomography  scan, barium meal) or current employ ment in a job 
requiring radiation exposure monitoring within [ADDRESS_496258] 
12 months (previous study  to be at least 4 months prior to check -in to the study  site 
where exposures are known to the investigator, or 6 months prior to check -in to the 
study  site for a radiolabeled drug study  where exposures are not known to the 
investigator). The total 12- month expo sure from this study  and a maximum of 2 other 
previous radiolabeled studies within 4 to 12 months prior to this study  will be within 
the Code of Federal Regulations (CFR) recommended levels considered safe, per 
[LOCATION_002] (US) Title [ADDRESS_496259] yle Considerations
The following guidelines are provided:
5.3.1. Meals and Dietary Restrictions
Participant s must abstain from all food and drink (except water) at least 4 hours prior 
to any  safety laboratory  evaluations and 8 hours prior to the collection of the predose 
PK sample.
Water is permitted until 1 hour prior to study  intervention administration.  Water may  
be consumed without restriction beginning 1 hour after dosing. Noncaffeinated drinks 
(except grapefruit or grapefruit- related citrus fruit juices—see below) may  be 
consumed with meals and the evening snack .
Lunch will be provided approximately  4hours after dosing .
Dinner will be provided approximately  9to 10 hours after dosing.
An evening snack may be permitted .

PF-07265803
Protocol C4411010
Final  Protocol, 26-January -2022
PFIZER CONFIDENTIAL
Page 26Participants will refrain from consumi ng red wine, grapefruit, or grapefruit -related 
citrus fruits (eg, Seville oranges, pomelos) from [ADDRESS_496260] dose of study  
intervention until collection of the final PK blood sample.  
While participants are confined, the irtotal daily  nutritional composition should be 
approximately  55% carbohy drate, 30% fat ,and 15% protein. The dail y caloric intake 
per participant should not exceed approximately  3200 kcal.
To help assure regularit y in bowel movements, nutritional composition should 
contain a t least 15 g of fiber per 1000 kcal or fiber capsules containing the equivalent 
amount of fiber may  be administered daily  (beginning at least 8 hr after dosing).
5.3.2. Caffeine, Alcohol, and Tobacco
Participant s will abstain from caffeine -
containing products for 24 hours prior to the 
start of dosing until collection of the final PK sample .  
Participant s will abstain from alcohol for 24 hours prior (or as specified above for red 
wine) to admission to the CRU and continue abstaining from alcohol until collection 
of the final PK sample. Participant s may  undergo urine alcohol test at the discretion 
of the investigator.
Participant s will abstain from the use of tobacco -or nicotine -containi ng products for 
3 months prior to dosing and during confinement in the CRU.
5.3.3. Activity
Participants will abstain from strenuous exercise (eg, heav y lifting, weight training, 
calisthenics, aerobics) for at least 48 hours prior to each blood collection for c linical 
laboratory  tests. Walking at a normal pace will be permitted;
In order to standardize the conditions on PKsampling day s, participant s will be 
required to refrain from ly ing down (except when required for BP, pulse rate , and 
ECG measurements), eati
ng, and drinking beverages other than water during the first 
4 hours after dosing;
5.3.4. Contraception
The investigator or his or her designee, in consultation with the participant , will confirm that 
the participant has selected an appropriate method of contrac eption for the individual 
participant and his or her partner(s) from the permitted list of contraception methods (see 
Appendix 4 Section 10.4.4 )and will confirm that the participant has been instructed in its 
consistent and correct use. At time points indicated in the SoA, the investigator or designee 
will info rm the participant of the need to use highly  effective contraception consistently  and 
correctly  and document the conversation and the participant ’s affirmation in the participant ’s 
chart ( participant s need to affirm their consistent and correct use of at least 1 of the selected 
methods of contraception) considering that their risk for pregnancy  may  have changed since 

PF-[ADDRESS_496261] the participant to call 
immediately  if the selected contraception method is discontinued or if pregnancy  is known or 
suspected in the participant or partner.
5.4.Screen Failures
Screen failures are defined as participants who consent to participate in the clinical study  but 
are not subsequently  enrolled in the study . Screen fail ure data are collected and remain as 
source and are not reported on the CRF .
Individuals who do not meet the criteria for participation in this study  (screen failure) may  be 
rescreened. 
6.STUDY INTERVENTION (S) AND CONCOMITANT THERAPY
Study  intervention is defined as an y investigational intervention(s), marketed product(s), 
placebo, medical device(s) , or study  procedure(s) intended to be administered to a study  
participant according to the study  protocol.
For the purposes of this protocol, study  intervention refers to 
PF-07265803.
6.1.Study Intervention(s) Administered
One batch of GMP [14C]PF -
07265803 API [INVESTIGATOR_394978] -diluted (100 µCi / 400 mg (~0.25 
µCi/mg)) to the overall specific activity  requirements 
for oral dosing. Abulk bottle of this will be shipped to the CRU from the radiochemical 
vendor.
[14C]PF -[ADDRESS_496262] (EDR) for the [14C] labeled oral formulation .
6.1.1. Administration
Following an overnight fast of at least 10 hours, participant s will receive study  intervention
at approximately  0800 hours (plus or minus 2 hours). Investigator site personnel will 
administer study  intervention according to the EDR.
In order to standardize the conditions on PK sampling day s, all participant s will be required 
to refrain from ly ing down (except when required for BP, pulse rate , and ECG 
measurements), eating, and drinking beverages other than water during the first [ADDRESS_496263] be stored in a secure, environmentally  controlled, and monitored 
(manual or automated recording) area in accordance with the labeled sto rage 
conditions with access limited to the investigator and authorized site staff. At a 
minimum, daily  minimum and maximum temperatures for all site storage locations 
must be documented and available upon request. Data for nonworking day s must 
indicate the minimum and maximum temperatures since previousl y documented for 
all site storage locations upon return to business.
3.Any excursions from the study  intervention label storage conditions should be 
reported to [COMPANY_007] upon discovery  along with an y actions taken. The site should 
activel y pursue options for returning the stud y intervention to the storage conditions 
described in the labeling, as soon as possible. Once an excursion is identified, the 
study  intervention must be quarantined and not used until [COMPANY_007] provides permission 
to use the study  intervention. Specific details regarding the definition of an excursion 
and information the site should report for each excursion will be provided to the site 
in the EDR/Roles and Responsibilities Matrix.
4.Any storage c onditions stated in the SRSD will be superseded by  [CONTACT_78254].
5.Study  interventions should be stored in their original containers.
6.See the EDR and the IP manual for storage conditions of the study  intervention once 
reconstituted and/or diluted.
7.The investigator, institution, or the head of the medical institution (where applicable) 
is responsible for stud y intervention accountability, reconciliation, and record 
maintenance (ie, receipt, reconciliation, and final disp osition records) , such as the 
IPAL or sponsor -approved equivalent .All study  intervention s will be accounted for 
using a study  intervention accountabilit y form/record as detailed in the IP manual.
8.Further guidance and information for the final disposition of unused study  
interventions are provided in the IP Manual .All destruction must be adequately  
documented. If destruction is authorized to take place at the investigator site, the 
investigator must ensure that the materials are destroy ed in compliance wit h 
applicable environmental regulations, institutional policy , and any  special instructions 
provided b y [COMPANY_007] asdetailed in the I P manual .
Upon identification of a product complaint, notify the sponsor w ithin 1 business day  
of discovery  as described in th e IP Manual .
6.2.1. Preparation and Dispensing
Within this protocol, preparation refers to the investigator site activities performed to make 
the study  intervention ready  for administration or dispensing to the participant by [CONTACT_394985]-07265803
Protocol C4411010
Final  Protocol, 26-January -2022
PFIZER CONFIDENTIAL
Page 29staff. Dispensing is defined as the provision of study  intervention , concomitant treatments, 
and accompan ying information by  [CONTACT_22806](s) to a healthcare provider, 
participant in accordance with this protocol and the I P Manual . Local health authority  
regulations or investigator site guidelines may  use alternative terms for these activities.
PF-[ADDRESS_496264] located in the IP 
Manual . Prepared doses will be provided in unit dose containers and labeled in accordance 
with [COMPANY_007] regulations and the investigator site’s labeling requirements.
6.3.Measures to Minimize Bias: Randomization and Bli nding
This study  is an open- label study .
6.3.1. Allocation to Study I ntervention
The investigator’s knowledge of the treatment should not influence the decision to enroll a 
particular participant or affect the order in which participant s are enrolled.
6.4.Study Intervention Compliance
When the individual dose for a participant is prepared from a bulk supply, the preparation of 
the dose will be confirmed by  a second qualified member of the study  site staff.
When participants are dosed at the site, they  will receive stud y intervention directly from the 
investigator or designee, under medical supervision. The date and time of each dose 
administered in the clinic will be recorded in the source documents and recorded in the CRF.  
The dose of stud y intervention and stud y participant identification will be confirmed at the 
time of dosing b y a member of the stud y site staff other than the person administering the 
study  intervention. Study site personnel will examine each participant’s mouth to ensure that 
the study  interve ntion was ingested.
6.5. Dose Modification
Not applicable.
6.6.Continued Access to Study Intervention A fter the End of the Study
No intervention will be provided to study  participants at the end of their study  participation.
6.7.Treatment of Overdose
For this study , any  dose of PF -07265803 greater than 400 mg (+/- 10% based on the 
preparation of the final oral dosing formulation) within a 24- hour time period [± 2hours] will 
be considered an overdose.
There is no specific treatment for an overdose.

PF-07265803
Protocol C4411010
Final  Protocol, 26-January -2022
PFIZER CONFIDENTIAL
Page 30In the event of an overdose, the investigator/treating phy sician should:
1.Contact [CONTACT_22840] 24 hours.
2.Closely  monitor the participant for an y AEs/SAEs and laboratory  abnormalities for at 
least 5 half -lives or 28 calendar day s after the overdose of PF-07265803 (whichever 
is longer).
3.Document the quantit y of the excess dose as well as the duration of the overdose in 
the CRF.
4.Overdose is reportable to [COMPANY_007] Safety  only when associated with an SAE.
5.Obtain a blood sample for PK anal ysis within as soon as possible from the date of the 
last dose of study  intervention if requested by  [CONTACT_7195] (determined on a 
case-by-case basis).
6.8.Concomitant Therapy
Use of prescription or nonprescription drugs and dietary  and herbal supplements are 
prohibite
d within 7 days or 5 half-lives (whichever is longer) prior to the first dose of 
study  intervention with theexception ofmoderate/potent CYP3A inducers which are
prohibited within [ADDRESS_496265] participant 
safet y or the overall results of the study may be permitted on a case -by-case basis (e.g. to 
treat an AE) following approval by  [CONTACT_456] . 
If an individual participant has not experienced a bowel movement within a 36 –48 hour 
window following dose administration, fluid intake should be increased and 
administration of a mild laxative (e.g., prune juice, milk of magnesia or a mild stool 
softener) should be implemented, with the goal to facilitate at least one daily  bowel 
movement. A mild laxative may  also be used prior to dosing to assist with collection of a 
pre-dose fecal sample, irrespective of the time of last bowel movement .
Acetaminophen/paracetamol may  be used at doses of ≤ 1 g/day .
Treatments taken within [ADDRESS_496266] dose of study intervention
will be documented as concomitant treatments.
6.8.1. Rescue Medicine 
There is no rescue therapy to reverse the AEs observed with PF-0726580 3; standard medical 
supportive care must be provided to manage the AEs. 

PF-07265803
Protocol C4411010
Final  Protocol, 26-January -2022
PFIZER CONFIDENTIAL
Page 317.DISCONTINUATION OF STUDY INTERVENTION AND PARTICIPANT 
DISCONTINUATION/WITHDRAWAL
7.1.Discontinuation of Stu dy Intervention
Since this is a single -dose study , this section is not applicable.
7.1.1. Potential Cases of Acute Kidney Injury
Abnormal values in SCr concurrent with presence or absence of increase in BUN that meet 
the criteria below, in the absence of other ca uses of kidney  injury , are considered potential 
cases of acute kidney  injury  and should be considered important medical events. 
An increase of ≥0.3 mg/dL (or ≥26.5 µ mol/L ) in SCr level relative to the participant’s own 
baseline measurement should trigger another assessment of SCr as soon as practicall y 
feasible, preferabl y within 48 hours from awareness.
If the second assessment (after the first observations of ≥0.3 mg/dL [ or ≥26.5 µ mol/L ]in SCr
relative to the participant’s own baseline measurement) is ≥0.4 mg/dL (or ≥35.4 µ mol/L ), the 
participant should be discontinued from the stud y and adequate, immediate, supportive 
measures taken to correct apparent acute kidney  injury .
Participants should return to the investigator site and be evaluated as soon as p ossible, 
preferabl y within 48 hours from awareness of the second assessment confirming abnormal 
SCr result. This evaluation should include laboratory  tests, detailed history , and phy sical 
assessment. In addition to repeating SCr, laboratory tests should in clude serum BUN, serum 
creatine kinase, and serum electrol ytes (including at a minimum potassium, sodium, 
phosphate/phosphorus, and calcium), in addition to urinary  dipstick, urine microscopic 
examination, and urinary indices. All cases confirmed on repeat testing as meeting the 
laboratory  criteria for acute kidney  injury , with no other cause(s) of laboratory  abnormalities 
identified, should be considered potential cases of drug- induced kidney  injury  irrespective of 
availability  of all the results of the in vestigations performed to determine etiology  of the 
abnormal SCr. If ≥2healthy  participants in a given period are noted to have 2 consecutive 
SCr results of ≥0.3 mg/dL (or ≥26.5 µ mol/L ), an assessment of whether the finding may  be 
considered an adverse dr ug reaction should be undertaken.
7.2.Participant Discontinuation/ Withdrawal F rom the Study
A participant may  withdraw from the study  at an y time at his/her own request. Reasons for 
discontinuation from the study  include the following:
Refused further study  procedures ;
Lost to follow -
up;
Death ;
Study  terminated by  [CONTACT_3211] ;

PF-07265803
Protocol C4411010
Final  Protocol, 26-January -2022
PFIZER CONFIDENTIAL
Page 32At the time of discontinuing from the stud y, if possible, an earl y discontinuation visit should 
be conducted. See the SoA for assessments to be collected at the time of study  
discontinuation and follow- up and for an y further evaluations that need to be completed. 
The early  discontinuation visit applies only  to participants who are enrolled/ randomized and 
then are prematurely
 withdrawn from the study .Participants should be questioned regarding 
their reason for withdrawal.  
If a participant withdraws from the study , he may  request destruction of any  remaining 
samples taken and not tested, and t he investigator must document any  such requests in t he 
site study  records and notify  the sponsor accordingly .
If the participant withdraws from the study  and also withdraws consent (see Section 7.2.1) 
for disclosure of future information, no further evaluations should be performed and no 
additional data should be collected. The sponsor may  retain and continue to use any  data 
collected before such withdrawal of consent.
7.2.1. Withdrawal of Conse nt
Participant s who request to discontinue receipt of study  intervention will remain in the study  
and must continue to be followed for protocol -specified follow -
up procedures. The onl y 
exception to this is when a participant specificall y withdraws consent for any further contact 
[CONTACT_78258]. Participant s should notify  the investigator in writing of the decision to withdraw 
consent from future follow -up, whenever possible. The withdrawal of consent should be 
explained in detail in the medical records b y the investigator, as to whether the withdrawal is 
only from further receipt of study  intervention or also from study  procedures and/or 
posttreat ment study  follow -up, and entered on the appropriate CRF page. In the event that 
vital status (whether the participant is alive or dead) is being measured, publicly  available 
information should be used to determine vital status only  as appropriatel y direct ed in 
accordance with local law.
7.3.Lost to Fol lowup 
A participant will be considered lost to follow- up if he or she repeatedl y fails to return for 
scheduled visits and is unable to be contact[INVESTIGATOR_530] b y the study  site.
The following actions must be taken if a participant fails to attend a required study  visit:
The site must attempt to contact [CONTACT_14315] . Counsel the participant on the importance of maintaining the 
assigned visit schedule and ascertain whe ther the participant wishes to and/or should 
continue in the study ;
Before a parti cipant is deemed lost to follow -up, the investigator or designee must 
make every  effort to regain contact [CONTACT_6635] (where possible, 3 telephone 
calls and, if nece ssary , a certified letter to the participant’s last known mailing 

PF-07265803
Protocol C4411010
Final  Protocol, 26-January -2022
PFIZER CONFIDENTIAL
Page 33address or local equivalent methods). These contact [CONTACT_14316]’s medical record ;
Should the participant continue to be unreachable, he/she will be consi dered to have 
withdrawn from the study. 
8.STUDY ASSESSMENTS AND PROCEDURES
The investigator (or an appropriate delegate at the investigator site) must obtain a signed and 
dated ICD before performing an y stud y-specific procedures.  
Study  procedures and thei r timing are summarized in the SoA. Protocol waivers or 
exemptions are not allowed.
Safety  issues should be discussed with the sponsor immediately  upon occurrence or 
awareness to determine whether the participant should continue or discontinue study  
intervention.
Adherence to the stud
y design requirements, including those specified in the SoA, is essential 
and required for stud y conduct.
All screening e valuations must be completed and reviewed to confirm that potential 
participants meet all eligibility  criteria. The investigator will maintain a screening log to 
record details of all participants screened and to confirm eligibility  or record reasons for 
screening failure, as applicable.
Health y participant s will be screened up to 28days prior to dosing to determine eligibility . If 
the time between screening and dosing exceeds 28 days as a result of unexpected delay s (eg, 
delay ed drug shipment), then participants do not require rescreening if the laboratory  results 
obtained prior to first dose administration meet eligibility  criteria.
A participant who qualified for this protocol but did not enroll from an earlier cohort/group 
may be used in a subsequent co hort/group without rescreening, provided laboratory  results 
obtained prior to the first dose administration meet eligibility  criteria for this study . In 
addition, other clinical assessments or specimen collections, eg, banked biospecimens, may  
be used without repeat collection, as appropriate.
Every  effort should be made to ensure that protocol -required tests and procedures are 
completed as described. However, it is anticipated that from time to time there may  be 
circumstances outside the control of the inv estigator that may  make it unfeasible to perform 
the test. I n these cases, the investigator must take all steps necessary  to ensure the safet y and 
well-being of the participant. When a protocol -required test cannot be performed, the 
investigator will document the reason for the missed test and an y corrective and preventive 
actions that he or she has taken to ensure that required processes are adhered to as soon as 
possible. The study  team must be informed of these incidents in a timely  manner.

PF-[ADDRESS_496267] information will be provided to the investigator site prior 
to initiation of the study .
The total blood sampling volume for individual participant s in this study  is approximately  
312mL. The actual collection times of blood sampling may  change. Additional blood 
samples may  be taken for safet y assessments at times specified b y [COMPANY_007], provided the total 
volume taken during the study  does not exceed 5 0
0mL during an y period of 56 consecutive 
days.
Table 1. Blood Sampling Volume
Sample Type Sample
Volume
(mL)Number ofSampling Times Total
Volume
(mL)Screening Study Period
Clinical Laboratory Tests 16 1 16
Clinical Laboratory Tests 8 2 16
PKofPF-07265803 4 15 60
Total r adioactivity (post-dose) 4 14 56
Total radioactivity (pre -dose) 10 1 10
Metabolite ID 10 15 150
Banked Biospecimen forDNA –Prep D1 4 1 4
TOTAL 312
To prepare for stud y participation, participant s will be instructed on the information in the 
Lifesty le Considerations and Concomitant Therapy sections of the protocol.
8.1.Efficacy Assessments
There are no efficacy  assessments included in this protocol.
8.2.Safety Assessments
Planned time points for all safety assessments are provided in the SoA.Unscheduled clinical 
laboratory  measurements may  be obtained at any  time during the stud y to assess any 
perceived safety  issues.
8.2.1. Physical Examinations
A complete physical examination will include , at a minimum, head, ears, eyes, nose, mouth, 
skin, heart and lung examinations, ly mph nodes, and gastrointestinal, musculoskeletal, and 
neurological s ystems. 
A brief physical examination will include, at a minimum, asse ssments of general appearance, 
the respi[INVESTIGATOR_2866] s ystems, and 
participant -reported s ymptoms.
Physical examinations may  be conducted by  a ph ysician, trained ph ysician's assistant, or 
nurse practitioner as acceptable according to local regu lation. 

PF-[ADDRESS_496268] physical 
examination findings that are identified during the active collection period and meet the 
definition of an AE or SAE ( Appendix 3)must be rep orted according to the processes in 
Sections 
8.3.1 to 8.3.3.
8.2.2. Vital Signs
Supi[INVESTIGATOR_394979] ’s arm supported at the level of the heart
, and 
recorded to the nearest mm Hgafter approximately  5minutes of rest . The same arm 
(preferabl y the dominant arm) will be used throughout the study
. Participant s should be 
instructed not to speak during measure ments.
The same properl y sized and calibrated BP cuff will be used to measure BP each time. The 
use of an automated device for measuring BP and pulse rate is acceptable; however, when 
done manuall y, pulse rate will be measured in the brachial/radial arte ry for at least 
30seconds. When the timing of these measurements coincides with a blood collection, BP 
and pulse rate should be obtained prior to the nominal time of the blood collection.
Additional collection times, or changes to collection times
,of BPand pulse rate will be 
permitted, as necessary, to ensure appropriate collection of safety  data.
8.2.3. Electrocardiograms
Standard 12-l ead ECGs utilizing limb leads should be collected at times specified in the SoA
section of this protocol using an ECG machine that automatically  calculates the heart rate and 
measures PR, QT, and QTc intervals and QRS complex .Alternative lead placement 
methodology  using torso leads (eg ,Mason -Likar) should not be used given the pote ntial risk 
of discrepancies with ECGs acquired using standard limb lead placement. All scheduled 
ECGs should be performed after the participant has rested quietly  for at least 5minutes in a 
supi[INVESTIGATOR_2547]. 
To ensure safet y of the participant s, a qualifi ed individual at the investigator site will make 
comparisons to baseline measurements. Additional ECG monitoring will occur if a) a 
postdose QTc Finterval is increased by  ≥60 msecfrom the baseline (predose) andis 
>450 msec; or b) an absolute QT value is ≥[ADDRESS_496269] 
hourly  until QTc values from 2 successive ECGs fall below the threshold value that triggered 
the repeat measurement.
If a) a postdose QTc Finterval remains ≥60msecfrom the baseline andis >450 msec; or b) 
an absolute QT value is ≥500 msecfor an y scheduled ECG for greater than 4 hours (or 
sooner , at the discretion of the investigator); or c) QTcFintervals get progressively longer, 
the participant should undergo continuous ECG monitoring (e.g. holter monitor) and 
consultation with a cardiologist. A cardiologist should be consulted if QTcF intervals do not 
return to less than the criteri alisted above after 8 hours of monitoring (or sooner ,at the 
discretion of the investigator).
In some cases, it may  be appropriate to repeat abnormal ECGs to rule out improper lead 
placement as contributing to the ECG abnormality. It is important that leads beplaced in the 
same positions each time in order to achieve precise ECG recordings. If a m achine -read QTc 
value is prolonged, as defined above, repeat measurements may  not be necessary  if a 
qualified medical provider’s interpretation determines that the QTcF values are in the 
acceptable range.
ECG values of potential clinical concern arelisted in Appendix 7.
8.2.4. Clinical Safety Laboratory Assessments
See Appendix [ADDRESS_496270] any  
clinically  relevant changes occurrin g during the study  in the AE section of the CRF. 
Clinically  significant abnormal laboratory  findings are those which are not associated with 
the underl ying disease, unless judged by  [CONTACT_78259]'s co ndition.
All laboratory  tests with values considered clinically  significantl y abnormal during 
participation in the study  or within [ADDRESS_496271] dose of stud y intervention should be 
repeated until the values return to normal or baseline or are no longer considered clinically  
significant b y the investigator or medical monitor.
If such values do not return to normal/baseline within a period of time judged reasonable by  
[CONTACT_093], the etiology  should be identified and the sponsor notified.
SeeAppendix 6for suggested actions and follow -
up assessments in the event of potential 
drug-induced liver injury.

PF-[ADDRESS_496272] be negative for participant s to receive study  
intervention .
8.2.5. COVID -19 specific assessments
Participants will be tested for SARS -COVID -19 infection by  [CONTACT_394986]. Additional testing may be required b y 
local regulations or b y the Principal Investigator.
8.3.Adverse Events ,Serious Adverse Events , and Other Safety Reporting
The definitions of an AE and an SAE can be found in Appendix 3.
AEs may  arise from s ymptoms or other complaints reported to the investigator by  [CONTACT_2416] (or, when appropriate, b y a caregiver, surrogate, or the participant's legall y 
authorized representative), or they  may  arise from cl inical findings of the Investigator or 
other healthcare providers (clinical signs, test results, etc.).
The investigator and an y qualified designees are responsible for detecting, documenting, and 
recording events that meet the definition of an AE or SAE a nd remain responsible to pursue 
and obtain adequate information both to determine the outcome and to assess whether the 
event meets the criteria for classification as an SAE or caused the participant to discontinue 
thestudy  
(see Section 7.1 ). 
During the active collection period as described in Section 8.3.1, e ach participant will be 
questioned about the occurrence of AEs in a nonleading manner.
In addition, the investigator may  be requested by  [CONTACT_19989] y to obtain specific follow -
up 
information in an expedited fashion.
8.3.1. Time Period and Frequency for C ollecting AE and SAE Information
The time period for actively  eliciting and collecting AEs and SAEs (“active collection 
period”) for each participant begins from the time the participant provides informed consent, 
which is obtained before the participant ’s participation in the study  (ie, before undergoing 
any study -related procedure and/or receiving study  intervention ), through and including a 
minimum of [ADDRESS_496273] 
SAE Report Form.
Investigators are not obligated to activel y seek information on AEsor SAE safter the 
participant has concluded study  participation. However, if the investigator learns of any  SAE, 
including a death, at an y time after a participant has completed the study , and he/she 
considers the event to be reasonabl y related to the study  intervention, the investigator must 
promptly  report the SAE to [COMPANY_007] using th e CT SAE Report Form .
[IP_ADDRESS].
Reporting SAEs to [COMPANY_007] Safety
All SAEs occurring in a participant during the active collection period as described in 
Section 8.3.[ADDRESS_496274] SAE Report Form immediately  upon 
awareness and under no circumstance should this exceed 24 hours, as indicated in 
Appendix 3. The investigator will submit any updated SAE data to the sponsor within 
24
hours of it being available.
[IP_ADDRESS]. Recording Nonserious AEs and SAEs on the CRF
All nonserious AEs and SAEs occurring in a participant during the active collection period, 
which begins after obtaining informed consent as described in Section 8.3.[ADDRESS_496275] on the CRF all directly  observed an
d all spontaneously  reported 
AEs and SAEs reported by  [CONTACT_2299].
Reporting of AEs and SAEs for participants who fail screening are participant to the CRF 
requirements as described in Section 5.4.
8.3.2. Method of Detecting AEs and SAEs
The method of recording, evaluating, and assessing causality  of AE sand SAE sand the 
procedures for completing and transmitting SAE reports are provided in Appendix 3.
Care will be taken not to introduce bias when detecting AEs and/or SAEs. Open -ended and 
nonleading verbal questioning of the participant is the preferred method to inquire about 
AEoccurrences.
8.3.3. Follow -
Up of AEs and SAEs
After the initial AE or SAE report, the investigator is required to proactively  follow each 
participant at subsequent visits/contacts. For each event, the investigator must pursue and 
obtain adequate information until resolution, stabilization, the event is otherwise explained, 
or the participant is lost to follow- up (as defined in Section 7.3).

PF-[ADDRESS_496276] the safet y of participants and the safet y of a 
study  intervention under clinical investigation are met.
The sponsor has a legal responsibility  to notify  both the local regulatory  authority  and other 
regulatory  agencies about the safet y of a stud y intervention under clinical investigation. The 
sponsor will comply  with country -specific regulatory  requirements relating to safet y 
reporting to the regulatory  autho rity, IRB s/ECs, and investigators.
Investigator safety  reports must be prepared for S[LOCATION_003]R saccording to local regulatory  
requirements and sponsor policy  and forwarded to investigators as necessary .
An investigator who receives S[LOCATION_003]Rs or other specific safe ty information (eg, summary  or 
listing of SAEs) from the sponsor will review and then file it along with the SRSD(s) for the 
study and will notify  the IRB/EC, if appropriate according to local requirements.
8.3.5. Environmental Exposure, Exposure During Pregnancy or Breastfeeding, and 
Occupational Exposure
Environmental exposure, occurs when a person not enrolled in the study  as a participant 
receives unplanned direct contact [CONTACT_216480]. Such exposure 
may or may  not lead to the occurrence of an AE or SAE. Persons at risk for environmental 
exposure include healthcare providers, famil y members, and others who may be exposed. An 
environmental exposure may  include exposure during pregnancy , exposure during 
breastfeeding, and occupati onal exposure.
Any such e xposure to the study  intervention under study  are reportable to [COMPANY_007] Safet y 
within 24 hours of investigator awareness.
[IP_ADDRESS]. Exposure During Pregnancy
An EDP occurs if:  
A male participant who is receiving or has discontinued study  intervention exposes a 
female partner prior to or around the time of conception .

PF-07265803
Protocol C4411010
Final  Protocol, 26-January -2022
PFIZER CONFIDENTIAL
Page 40A female is found to be pregnant while being exposed or having been exposed to 
study  intervention due to environmental exposure. Below are examples of 
environmental EDP :  
Amale famil y member or healthcare provider who has been exposed to the study  
intervention by  [CONTACT_78262], inhalation, or skin contact [CONTACT_240854] .
The investigator must report EDP to [COMPANY_007] Safet y within 24 hours of the in
vestigator’s 
awareness, irrespective of whether an SAE has occurred. The initial information submitted 
should include the anticipated date of delivery  (see below for information related to 
termination of pregnancy). 
If EDP occur s in a participant or a participant’s partner, the investigator must report 
this information to [COMPANY_007] Safety on the CT SAE Report Form and an EDP 
Supplemental Form, regardless of whether an SAE has occurred. Details of the 
pregnancy  will be collected afte r the start of stud y intervention and until [ADDRESS_496277] dose.
If EDP occurs in the setting of environmental exposure, the investigator must report 
information to [COMPANY_007] Safety  using the CT SAE Report Form and EDP Supplemental 
Form. Since the exposure information does not pertain to the participant enrolled in 
the study , the information is not recorded on a CRF; however, a copy  of the 
completed CT SAE Report Form is maintained in the investigator site file.
Follow -up is conducted to obtain general information on the pregnancy  and its outcome for 
all EDP reports with an unknown outcome. The investigator will follow the pregnancy  until 
completion (or until pregnancy  termination) and notify  [COMPANY_007] Safet y of the outcome as a 
follow -up to t he initial EDP S upplemental Form. In the case of a live birth, the structural 
integrit y of the neonate can be assessed at the time of birth. In the event of a termination, the 
reason(s) for termination should be specified and, if clinically  possible, the s tructural 
integrit y of the terminated fetus should be assessed by [CONTACT_4692] (unless 
preprocedure test findings are conclusive for a congenital anomal y and the findings are 
reported).
Abnormal pregnancy  outcomes are considered SAEs. If the out come of the pregnancy  meets 
the criteria for an SAE (ie, ectopic pregnancy , spontaneous abortion, intrauterine fetal 
demise, neonatal death, or congenital anomal y in a live -born bab y, a terminated fetus, an 
intrauterine fetal demise, or a neonatal death), the investigator should follow the procedures 
for reporting SAEs. Additional information about pregnancy  outcomes that are reported to 
[COMPANY_007] Safety  as SAEs follows: 
Spontaneous abortion includ ingmiscarriage and missed abortion;
Neonatal deaths that occu r within [ADDRESS_496278] 
to causality , as SAEs. In addition, infant deaths after 1 month should be reported as 

PF-07265803
Protocol C4411010
Final  Protocol, 26-January -2022
PFIZER CONFIDENTIAL
Page 41SAEs when the investigator assesses the infant death as related or possibly  related to 
exposure to the study  intervention. 
Additional information regarding the EDP may  be requested by  [CONTACT_456]. Further 
follow -
up of birth outcomes will be handled on a case- by-case basis (eg, follow -up on 
preterm infants to identify developmental delay s). In the case of paterna l exposure, the 
investigator will provide the participant with the Pregnant Partner Release of Information 
Form to deliver to his partner. The investigator must document in the source documents that 
the participant was given the Pregnant Partner Release of Information Form to provide to his 
partner.
[IP_ADDRESS]. Exposure During Breastfeeding
An exposure during breastfeeding occurs if: 
A female is found to be breastfeeding while being exposed or having been exposed to 
study  intervention (ie, environmental exposure). An example of environmental 
exposure during breastfeeding is a female family  member or healthcare provider who 
reports that she is breastfeeding after having been exposed to the study  intervention 
by [CONTACT_78262], inhalation, or skin contact .  
The investigator must report exposure during breastfeeding to [COMPANY_007] Safety  within 24 hours 
of the investigator’s awareness, irrespective of whether an SAE has occurred. The 
information must be reported using the CT SAE Report Form. When exposure during 
breastfeeding occur s in the setting of environmental exposure, the exposure information does 
not pertain to the participant enrolled in the stud y, so the information is not recorded on a 
CRF. However, a cop y of the completed CT SAE Report Form is maintained in the 
investigat or site file.
An exposure during breastfeeding report is not created when a [COMPANY_007] drug specificall y 
approved for use in breastfeeding women (eg, vitamins) is administered in accord with 
authorized use. However, if the infant experiences an SAE associated with such a drug, the 
SAE is reported together with the exposure during breastfeeding.
[IP_ADDRESS]. Occupational Exposure
The investigator must report any  instance of occupational exposure to [COMPANY_007] Safet y within 24 
hours of the investigator’s awareness 
using the CT SA E Report Form regardless of whether 
there is an associated SAE. Since the information about the occupational exposure does not 
pertain to a participant enrolled in the study , the information is not recorded on a CRF; 
however, a cop y of the completed CT SAE Report Form must be maintained in the 
investigator site file .
8.3.6. Cardiovascular and Death Events
Not applicable.

PF-07265803
Protocol C4411010
Final  Protocol, 26-January -2022
PFIZER CONFIDENTIAL
Page 428.3.7. Disease -Related Events and/or Disease -Related Outcomes Not Qualifying as AEs 
or SAEs
Not applicable.
8.3.8. Adverse Events of Special Interest
Not applicable.
[IP_ADDRESS]. Lack of Efficacy
This section is not applicable because efficacy  is not expected in the study  population .
8.3.9. Medical Device Deficiencies
Not applicable.
[IP_ADDRESS]. Medication Errors
Medication errors may  result from the administration or consumption of the 
study 
intervention by [CONTACT_19995] , or at the wrong time, or at the wrong dosage strength.
Exposures to the study  intervention under stud y may occur in clinical trial settings, such as 
medication errors.
Safety Event Recorded on the CRF Reported on the CT SAE Report 
Form to [COMPANY_007] Safety Within 
24 Hours of Awareness
Medication errors All (regardless of whether 
associated with an AE)Only  if associated with an SAE
Medication errors include:
Medication errors involving participant exposure to the study  intervention ;
Potential medication errors or uses outside of what is foreseen in the protocol that do 
or do not involve the study participant .
Such medication errors occurring to a stud
y participant are to be captured on the medication 
error page of the CRF, which is a specific version of the AE page.
In the event of a medication dosing error, the sponsor should be notified within 24 hours .
Whether or not the medication error is accompanied by  [CONTACT_1149], as determined by  [CONTACT_1275], the medication e rror is recorded on the medication error page of the CRF and, if 
applicable, an y associated AE(s), serious and nonserious, are recorded on theAE page of the 
CRF.

PF-[ADDRESS_496279] SAE Report 
Form onl y when associated with an SAE .
8.4.Pharmacokinetics 
The samples collected for PK (non- radiolabeled PF-07265803 concentration s), radioactivit y
(total 14C) and/or metabolite profiling assessment must beprocessed andshipped asindicated
inthe instructions provided totheinvestigator sitetomaintain sample integrity .Any
deviations from the sample handling procedure (eg, sample collection and processing steps, 
interim storage orshippi[INVESTIGATOR_19944]), including any actions taken, must be docum ented and 
reported tothesponsor. Onacase-by-case basis, the sponsor may make adetermination as to 
whether sample integrity has been compromised. Samples collected for PK, radio activity
and/or metabolite profiling/ID may  also be used to evaluate safety or efficacy  aspects related 
to concerns arising during or after the study , for metabolite identification and/or evaluation of 
the bioanal yticalmethod, or for other internal exploratory purposes. Genetic anal ysis will not 
be performed on these samples unl ess consent for this was included in the informed consent.  
Participant confidentiality will be maintained.
8.4.1. Plasma Analysis of Non-Radiolabeled PF-07265803
Blood samples of approximately  4 mL , will be collected into appropriately  labeled tubes 
containing K 2EDTA at times specified in the SoA of the protocol to provide 
approximately
1.5 mL  plasma, will be collected for measurement of plasma concentrations of PF-07265803
and metabolites as specified in the Bioanal yticalPlan. Instruction s for the collection and 
handling of biological samples will be provided in the lab oratory manual or by  [CONTACT_456]. 
The actual date and time (24-hour clock time) of each sample will be recorded. The 
concetrations of “cold” PF-[ADDRESS_496280] nominal time relative to dosing. Collection of 
samples up to and including 10 hours after dose administration that are obtained within 
10% of the nominal time relative to dosing (eg, within 6 minutes of a 60 - minute sample) will 
not be captured as a protocol deviation, as long as the exact time of the collection is noted on 
the source document and the CRF. Collection of samples more than 10 hours after dose
administration that are obtained ≤
1hour away  from the nominal time relative to dosing will 
not be captured as a protocol deviation, as long as the exact time of the collection is noted on 
the source document and theCRF. This protocol deviation window does not apply  to samples 
to be collected more than 10 hours after dose administration at outpatient/follow -up visits 
with visit windows.
Samples collected for analy ses of  plasma concentration may  also be used to evaluate safet y 
or efficacy  aspects related to concerns arising during or after the study , for metabolite 
identification and/or evaluation of the bioanal ytical method, or for other internal exploratory  
purposes.

PF-07265803
Protocol C4411010
Final  Protocol, 26-January -2022
PFIZER CONFIDENTIAL
Page 448.4.2. Metaboli te Profiling/ID
[IP_ADDRESS]. Plasm a for Metaboli teProfiling/ID
Blood samples (10 mL) to provide plasma, will be collected into appropriately labeled tubes
containing K2EDTA at times specified in the SoA section of the protocol. Handling of 
plasma samples, including procedures to stabilize metabolites will be addressed in the 
Laboratory  Manual. 
[IP_ADDRESS]. Urine for Metaboli te Profiling/ID
Urine will be collected over intervals described in the SoA section of the protocol. Handling 
of urine samples, including procedures to stabilize metabolites will be addressed in the 
Laboratory  Manual.
Prior to dosing on Day [ADDRESS_496281] empty his urinary bladder, and
analiquot from thisurine willserve as the “urine blank”. Approximately  10 mL  of urine 
will be collected predose for analysis. 
Following dosing on Day [ADDRESS_496282] dose will be collected and saved in a 
container and stored in refrigerated conditions (ie, 2-8°C) for the duration of the
collect ion interval. An aliquot of approximately  100 mL  from each collection interval 
will be withdrawn for measurement of metabolite concentrations/profiling.
At the end of the collection interval, subjects will attempt to empty  bladder prior to the 
start of the next interval with thisvoid included aspartoftheinterval collection;
Ifendofurine collection interval coincides with ameal, subjects willattempt to void
prior to initiation of the meal ;in such cases, so long astheactual time offorced void
isrecorded, for practical reasons ,thefact that this collection may be more than 30 -
minutes (and up to 45- minutes) prior toendofcollection interval isacceptable and
will not be considered as protocol deviation.
The urine container will be mixed thoroughly and total weight of the urine collected
during theinterval recorded
[IP_ADDRESS]. Feces for Metabolite Profiling/ID
All feces will be collected over intervals described in the SoA section of the protocol. 
A pre -dose sample will also be collecte d.When feces are being collected, all  toilet 
paper that come in contact [CONTACT_1155]’s feces will also be collected for possible 
analysis in appropriatel y labelled containers stored at approximately  -20°C .  In the 
event of diarrhea during the study , all diarrhea including any  swabbing and 
contaminated linen should be collected, labeled, and stored in appropriate containers 
at approximately  -20°C for possible anal ysis of radioactivity .Prior to dosing on Da y
[ADDRESS_496283] complete a fecal void. A mild laxative may be used 
to promote a bowel movement and complete fecal void to improve radiolabel material 
recovery .Approximately 15 g o f feces will be collected predose for anal ysis.For 

PF-07265803
Protocol C4411010
Final  Protocol, 26-January -2022
PFIZER CONFIDENTIAL
Page 45each c ollection interval , an aliquot of 40 g will be withdrawn for metabolic
identification and profiling. A mild laxative may  be used to promote a bowel 
movement in concordance with the guidance inSection 6.8.Detailed sample handling 
instructions will be provided separately to the site before the start of the study .
8.4.3. Radioactivity
[IP_ADDRESS]. Sample Collection
It is extremely  important to quantitatively  collect all scheduled blood, urine, feces and 
emesis samples.  The separate collection of urine and feces is critical to the success of this 
study .
  Ifurine and feces becomes mixed at an ycollection, note the we ightand add the 
feces -contaminated urine to the feces collection.  Samples missed or lost for an y reason
should be documented on the case report forms (CRFs).
[IP_ADDRESS]. Plasma /Blood Sample Collection for Total Radioactivity
Blood samples ( 4 mL ) to provide plasma (10 mL predose) , will be collected into 
appropriatel ylabeled tubes containing K2EDTA at times specified in the SoA section of the 
protocol and submitted for analy sisof total radioactivity .Detailed sample handling 
instructions wil l beprovided separately to the site before the start of the study and described 
in the Laboratory  Manual .
[IP_ADDRESS]. Urine Sample Collection for Total Radioactivity
Urine will be collected over intervals described in the SoA.A predose aliquot of [ADDRESS_496284] dose collection interval will 
bewithdrawn for total radioactivity analy sis.Detailed sample handling instructions will be
provided separately to the site before the start of the study and described in the Laboratory  
Manual.
[IP_ADDRESS]. Fecal Sample Collection for Total Radioactivity
Feces will be collected over intervals described in the SoA.A predose aliquot of [ADDRESS_496285] d ose collection interval ,an aliquot of 100 g will be withdrawn for 
total radioactivity measurements. Detailed sample handling instructions will be provided 
separately to the site before the start of the study and described in the Laboratory  Manual .
[IP_ADDRESS]. Emesis Sample Collection for Total Radioactivity
If emesis occurs within the first [ADDRESS_496286] bodily  discharge (eg, nose bleeding clean -up tissue and any  emesis related clean- up) 
should be collected and stored in a labeled emesis bag at minimally  -20°C for possible 
analysis of radi oactivity .  Detailed sample handling instructions will be provided separatel y 
to the site before the start of the study .

PF-07265803
Protocol C4411010
Final  Protocol, 26-January -2022
PFIZER CONFIDENTIAL
Page 468.5.Genetics
8.5.1. Specified Genetics
Genetics (specified anal yses) are not evaluated in this study .
8.5.2. Retained Research Samples for Genetics
A 4-mL blood sample optimized for DNA isolation Prep D1will be collected according to the 
SoA,as local regulations and I RBs/ECs allow.
Retained Research Samples may be used for research related to thestudy  intervent ion(s). 
Genes and other analy tes (eg ,proteins, RNA, nondrug metabolites) may  be studied using the 
banked samples. 
See Appendix 5for i
nformation regarding genetic research. Details on processes for 
collection and shipment of these samples can be found in Laboratory Manual .
8.6.Biomarkers
Biomarkers are not evaluated in this study .
8.6.1. Specified Gene Expression (RNA) Research 
Specified gene expression (RNA) research is not included in this study .
8.6.2. Specified Protein Research 
Specified protein research is not included in this study .
8.6.3. Specified Metabolomic Research 
Specified metabolomic research is not included in this study .
8.7.Immunogenicity Assessments
Immunogenicit y assessments are not included in this study .
8.8.Health Economics
Health e conomics/ medical resource utilization and health e conomics parameters are not 
evaluated in this study .
9.STATISTICAL CONSIDER
ATIONS
Detailed methodology  for summary  and statistical anal yses of the data collected in this study  
is outlined here and fur ther detailed in a SAP, which will be maintained b y the sponsor. The 
SAP may  modify  what is outlined in the protocol where appropriate; however, any  major 
modifications of the primary  endpoint definitions or their anal yses will also be ref lected in a 
protocol amendment.

PF-07265803
Protocol C4411010
Final  Protocol, 26-January -2022
PFIZER CONFIDENTIAL
Page 479.1.Statistical Hypotheses
No statistical hy pothesis is tested in this study .
9.2.Analysis Sets
For purposes of analy sis, the following anal ysis sets are defined in the table below :
Table 2. A nalysis Sets
Participant Analysis 
SetDescription
Enrolled "Enrolled" means a ll participants who complete the informed 
consent process .
Safety Anal ysis Set All participants assigned to study  intervention and who take at 
least [ADDRESS_496287] 1 measurable concentration of PF -
07265803. The PK concentration population for 14C is defined 
as all participant s dosed with [14C]PF -07265803, who have at 
least one 14C measurement.
Extent of Excretion Extent of excretion population is defined as all participants
who have received 1dose of [14C]PF -[ADDRESS_496288]
evaluable total radioactivity concentration (urinary and fecal) 
data and who had no protocol deviations or AEs (such as 
vomiting of the dose, diarrhoea or severe constipation) that 
may have affected the extent of excretion analy sis.
PK Parameter The PK parameter analy sispopulation for PF-[ADDRESS_496289]. The PK concentration and PK parameter analy sis
sets may differ.
9.3. Statistical Analyses
The SAP will be developed and finalized before any anal yses are pe rformed and will 
describe the anal yses and procedures for accounting for missing, unused, and spurious data. 
This section is a summary of the planned statistical analy ses of the primary  and secondary  
endpoints.
9.3.1. General Considerations
The SAP will be developed and finalized before anyanaly ses are performed and will
describe the analy sesand procedures for accounting for missing, unused, and spurious 

PF-07265803
Protocol C4411010
Final  Protocol, 26-January -2022
PFIZER CONFIDENTIAL
Page 48data. This section is a summary  of the planned statistical analy sesof the primary and 
secondary endpoints.
9.3.2. Primary Endpoint(s)
Radioactivity  excreted in urine and/or feces will be reported as the percentage of the 
administered radioactivity excreted at each time interval, cumulativel y through that interval 
and the total percent of dose recovered in urine and/or feces.
Percent recovery and cumulative recovery of total radioactivity in urine, feces and emesis (if 
any) will be determined based on total administered dose.
Individual participant and median data profiles will be graphically  presented for the
cumulative recovery of radioactivity in urine, feces and their combination. The to
tal 
recovery of radioactivity in urine, feces and their combination will be listed and summarized
using descriptive statistics. Where possible, therateofexcretion of radioactivity will be
estimated.
[IP_ADDRESS]. Metabolic Profiling/Identification
Plasma, urine and fecal samples will be analy zed formetabolites and/or chiral inversion
ofPF-07265803. Major metabolites and/or stereoisomers of PF- 07265803 in plasma, 
urine, and feces following oral dose of [14C]PF-07265803 will be identified.  
Contributions of each major metabolite to total radioactivity recovered and to circulating 
radioactivity in plasma will be approximated. Results of the metabolic profiling analy sis
will be detailed in a separate report and will be summarized within the CSR.
9.3.3. Secondary Endpo int(s)
[IP_ADDRESS]. Pharmacokinetic Parameters
[IP_ADDRESS].1. Plasma
The PK parameters for PF -07265803 and for known circulating metabolites PF-07327859, 
PF-07327860, PF -07327890 and total radioactivity will be derived following a single dose 
administration of 
[14C]PF-07265803 ,wher eappropriate, from theconcentration -time
profiles as outlined below. Additional PK parameters may  be included at the discretion of 
the sponsor and described in the Statistical Analysis Plan.
The PF-07265803 (including  circulating metabolites PF- 07327859, PF -07327860, PF -
07327890) 
and total radioactivity (plasma) concentrations and parameters (below) will 
be listed and summarized using descriptive statistics. Individual subject and median
concentration -time profiles will be graphically presented.

PF-[ADDRESS_496290] 
quantifiable concentration Linear/Log trapezoidal rule
AUC infaArea under the concentration-
time curve from time zero to 
infinityAUC last+(Clast*/k el), where C last*is the
predicted plasma concentration at the
last quantifiable time point estimated 
from the log -linear regression analy sis
Cmax Maximum observed 
concentrationObserved directly from data
Tmax Time of maximum observed 
concentrationObserved directly  from data as time of
firstoccurrence
t½aTerminal elimination half-life Loge(2)/k el,where k elis the terminal
phase rate constant calculated by a linear 
regression of the loglinear concentration
time curve. Only those data points
judged to describe the terminal loglinear
decline will be used in the regression
CL/Fa(oral) Apparent clearance of drug from 
e.g.,plasma, for extravascular 
routes of administrationDose/AUC inf
Vz/Fa(oral) Apparent volume of distribution, 
estimated from terminal phase, 
for extravascular dosingDose/(AUC inf*kel)
a. Where appropriate
9.3.4. Other Safety Analyses
All safet y anal yses will be performed on the safet y population.
AEs, ECGs, BP, pulse rate, and safety  laboratory  data will be reviewed and summarized on 
an ongoing basis during the study  to evaluate the safet y of participants. An y clinical 
laboratory , ECG, BP, and pulse rate abnormalities of p otential clinical concern will be 

PF-07265803
Protocol C4411010
Final  Protocol, 26-January -2022
PFIZER CONFIDENTIAL
Page 50described. Safet y data will be presented in tabular and/or graphical format and summarized 
descriptivel y, where appropriate.
Medical history  and phy sical examination and neurological examination information, as 
applicable, collected during the course of the study  will be considered source data and will 
not be required to be reported, unless otherwise noted. However, an y untoward findings 
identified on phy sical and/or neurological examinations conducted during the active 
collection period will be captured as AEs, if those findings meet the definition of an AE.  
Data collected at screening that are used for inclusion/exclusion criteria, such as laboratory  
data, ECGs, and vital signs, will be considered source data, and will no t be required to be 
reported, unless otherwise noted. Demographic data collected at screening will be reported.
[IP_ADDRESS]. Electrocardiogram Analyses
Absolute value and c hanges from baseline for the ECG parameters QT interval, heart rate, 
QTc interval, PR interval, and QRS complex will be listed by [CONTACT_22841].
[IP_ADDRESS]. Other Analyses
Pharmacogenomic or biomarker data from Banked Biospecimens may be collected during or 
after the trial and retained for future analy ses;the results of such analy sesare not planned to
be included in the CSR
9.4.Interim Analyses
No formal interim anal ysis will be conducted for this study . As this is an open- label 
study ,the sponsor may  conduct unblinded reviews of the data during the course of the study  
for the purpose of safet y assessment, facili tating PK/PD modeling, and/or support ingclinical 
development. 
9.5.Sample Size Determination
A sample size of [ADDRESS_496291] 4 participants provide evaluable data; wi th intent not to 
replace participants who prematurel y withdraw (or offer non- evaluable or partially  evaluable 
data).

PF-07265803
Protocol C4411010
Final  Protocol, 26-January -2022
PFIZER CONFIDENTIAL
Page 5110. SUPPORTING DOCUMENTA TION AND OPERATIONAL CONSIDERATIONS
10.1. Appendix 1: Regulatory, Ethical, and Study Oversight Considerations
10.1.1. Regulatory and Ethical Considerations
This study  will be conducted in accordance with the protocol and with the following:
Consensus ethical principles derived from international guidelines , including the 
Declaration of Helsinki and CI OMS International Ethical Guidelin es;
Applicable ICH GCP guidelines;
Applicable laws and regulations , including applicable privacy  laws .
The protocol, protocol amendments, I CD, SRSD(s) , and other relevant documents 
(eg,advertisements) must be 
reviewed and approved by  [CONTACT_456] ,submitted to an I RB/EC 
by [CONTACT_093], and reviewed and approved by  [CONTACT_1201]/EC before the study  is initiated.
Any amendments to the protocol will require IRB/EC approval before implementation of 
changes made to the study design, except for changes nec essary  to eliminate an immediate 
hazard to study  participants.
Protocols and an y substantial amendments to the protocol will require health authority  
approval prior to initiation except for changes necessary to eliminate an immediate hazard to 
study  partic ipants.
The investigator will be responsible for the following:
Providing written summaries of the status of the study  to the IRB/EC annually  or 
more frequently  in accordance with the requirements, policies, and procedures 
established by  [CONTACT_1201]/EC ;
Notify ing the IRB/EC of SAEs or other significant safet y findings as required by 
[CONTACT_1744]/EC procedures;
Providing oversight of the conduct of the stud y at the site and adherence to 
requirements of 21 CFR, ICH GCP guidelines, the I RB/EC, European regulation 
536/2014 for clinical studies (if applicable), European Medical Device Regulation 
2017/745 for clinical device research (if applicable), and all other applicable local 
regulations .
[IP_ADDRESS]. Reporting of Safety Issues and Serious Breaches of the Protocol or ICH GCP
In the event of any  prohibition or restriction imposed (ie, clinical hold) by  [CONTACT_78270] y in any area of the world, or if the investigator is aware of an y new 
information that might influence the evaluation of the benefits and risks of the study 
intervention , [COMPANY_007] should be informed immediately .  

PF-[ADDRESS_496292], and 
of an y serio us breaches of this protocol or of the ICH GCP guidelines that the investigator 
becomes aware of.
10.1.2. Financial Disclosure
Investigators and subinvestigators will provide the sponsor with sufficient, accurate financial 
information as requested to allow the sponsor to submit complete and accurate financial 
certification or disclosure statements to the appropriate regulatory  authorities. Investigators 
are responsible for providing information on financial interests during the course of the stud y 
and for 1 year after completion of the study .
10.1.3. Informed Consent Process
The investigator or his/her representative will explain the nature of the study , including the 
risks and benefits, to the participant  and answer all questions regarding the study .The 
participant  should be given sufficient time and opportunity  to ask questions and to decide 
whether or not to participate in the trial.
Participants must be informed tha t their participation is voluntary . Participants  will be 
required to sign a statement of informed consent that meets the requirements of 21 CFR 50, 
local regulations, ICH guidelines, privacy  and data protection requirements, where 
applicable, and the IRB/EC or study  center.
The investigator must ensure that each study  participant  is fully  informed about the nature 
and objectives of the study, the sharing of data related to the study ,and possible risks 
associat ed with participation, including the risks associated with the processing of the 
participant ’s personal data. 
The participant must be informed that his/her personal study -related data will be used by  [CONTACT_394987] w. The level of disclosure must also be 
explained to the participant.
The participant must be informed that his/her medical records may  be examined by  [CONTACT_160439], by  
[CONTACT_216203] e IRB/EC members, and b y inspectors from regulatory authorities.
The investigator further must ensure that each study  participant   is fully  informed about his 
or her right to access and correct his or her personal data and to withdraw consent for the 
proce ssing of his or her personal data.
The medical record must include a statement that written informed consent was obtained 
before the participant was enrolled in the study  and the date on which 
the written consent was 
obtained. The authorized person obtaining the informed consent must also sign the ICD.

PF-[ADDRESS_496293] current version of the IC D(s) during their 
participation in the study .
A cop y of the IC D(s) must be provided to the participant.
10.1.4. Data Protection
All parties will comply  with all applicable laws, including laws regarding the implementation 
of organizational and technical measures to ensure protection of participant data.
Participants’ personal data will be stored at the study  site in [encry pted electronic and/or 
paper] form and will be [password
-protected or secured in a locked room] to ensure that onl y 
authorized study  staff have access. The study  site will implement appropriate technical and 
organizational measures to ensure that the personal data can be recovered in the event of 
disaster. In the event of a potential personal data breach, the study site will be responsible for 
determining whether a personal data breach has in fact occurred and, if so, providing breach 
notifications as required by  [CONTACT_2371].
To protect the rights and freedoms of participants with regard to the processing of personal 
data, participants will be assigned a single, participant -specific numerical code. Any  
participant records or data sets that are transferred to the sponsor will contain the nume rical 
code; participant names will not be transferred. All other identifiable data transferred to the 
sponsor will be identified by  [CONTACT_20007], participant-specific code. The study  site will 
maintain a confidential list of participant s who participated in the study, linking each 
participant ’s numerical code to his or her actual identity and medical record ID. In case of 
data transfer, the sponsor will protect the confidentiality  of participant s’ personal data 
consistent with the c linical study agreement and applicable privacy  laws.
10.1.5. Committees Structure
[IP_ADDRESS]. Data Monitoring Committee 
This study  will not use a DMC or IOC .
10.1.6. Dissemination of Clinical Study Data
[COMPANY_007] fulfills its commitment to publicly  disclose clinical study  results through posting the 
results of studies on www.clinicaltrials.gov (ClinicalTrials.gov), the EudraCT, and/or 
www.pfizer.com, and other public registries in accordance with applicable local 
laws/regulations. In addition, [COMPANY_007] reports study  results outside of the requ irements of local 
laws/regulations pursuant to its SOPs.
In all cases, stud y results are reported b y [COMPANY_007] in an objective, accurate, balanced, and 
complete manner and are reported regardless of the outcome of the stud y or the country in 
which the study  was conducted.

PF-07265803
Protocol C4411010
Final  Protocol, 26-January -2022
PFIZER CONFIDENTIAL
Page 54www.clinicaltrials.gov
[COMPANY_007] posts clinical trial results on www.clinicaltrials.gov for [COMPANY_007]- sponsored interventional 
studies (conducted in patients) that evaluate the safety  and/or efficacy  of a product, 
regardless of the geographical location in which the study  is conducted. These r esults are 
submitted for posting in accordance with the format a nd timelines set forth by  [CONTACT_20008].
EudraCT
[COMPANY_007] posts clinical trial r esults on EudraCT for [COMPANY_007] -sponsored interventional studies in 
accordance with the format and timelines set forth by  [CONTACT_20009].
www.pfizer.com
[COMPANY_007] posts public disclosure s ynopses (CSR synopses in which an y data that could be used 
to identify  individual participants have been removed) on www.pfizer.com for 
[COMPANY_007] -sponsored interventional studies at the same time the corresponding study  results are
posted to www.clinicaltrials.gov .
Documents within marketing authorization packages/submissions
[COMPANY_007] complies with the European Union Policy  0070, the proactive publication of clinical 
data to the EMA website. Clinical data, under Phase 1 of this po licy,includes clinical 
overviews, clinical summaries, C SRs, and appendices containing the protocol and protocol 
amendments, sample CRF s, 
and statistical methods. Clinical data, under Phase 2 of this 
policy ,includes the publishing of individual participan tdata. Policy  0070 applies to new 
marketing authorization applications submitted via the centrali zed procedure since 
01January 2015 and applications for line extensions and for new indications submitted via 
the centralized procedure since 
01 July  2015.
Data sharing
[COMPANY_007] provides researchers secure access to patient- level data or full CSRs for the purposes 
of “bona -fide scientific research” that contribute sto the scientific understanding of the 
disease, target, or compound class. [COMPANY_007] will make data from these trials available 
24months after study  completion. Patient- level data will be anon ymized in accordance with 
applicable privacy  laws and regulations. CSRs will have personally  identifiable information 
redacted.
Data requests are considered from qualified researchers with the appropriate competencies to 
perform the proposed analyses. Research teams must include a biostatistician. Data will not 
be provi ded to applicants with significant conflicts of interest, including individuals 
requesting access for commercial/competitive or legal purposes.

PF-07265803
Protocol C4411010
Final  Protocol, 26-January -2022
PFIZER CONFIDENTIAL
Page 5510.1.7. Data Quality Assurance
All participant data relating to the study will be recorded on printed or electronic CRF unless 
transmitted to the sponsor or designee electronically  (eg, laboratory  data). The investigator is 
responsible for verify ing that data entries are accurate and correct by  [CONTACT_20010].
Guidance on completion of CRFs wil l be provided in the CRF Completion Requirements 
document.
The investigator must ensure that the CRFs are securel y stored at the study site in encrypted 
electronic and/or paper form and are password -protected or secured in a locked room to 
prevent access b y unauthorized third parties.
QTL s are predefined parameters that are monitored during the study . Important deviations 
from the QTLs and any remedial actions taken will be summarized in the clinical study  
report.
The investigator must permit study -related monitoring, audits, IRB/EC review, and 
regulatory  agency  inspections and provide direct access to source data documents. This 
verification may  also occur after study  completion. I t is important that the investigator(s) and 
their relevant personnel are avai lable during the monitoring visits and possible audits or 
inspections and that sufficient time is devoted to the process.
Monitoring details describing strategy , including definition of study  critical data items and 
processes (eg, risk- based initiatives in operations and quality ,such as risk management and 
mitigation strategies and analytical risk-based monitoring), methods, responsibilities ,and 
requirements, including handling of noncompliance issues and monitoring techniques 
(central, virtual , or on- site monitoring) , are provided in the data management plan and 
monitoring plan maintained and utilized by  [CONTACT_36613].
The sponsor or designee is responsible for the data management of this study ,including 
quality  checking of the data.
Records and documents, including signed ICD s, pertaining to the conduct of this study  must 
be retained b y the investigator for 15years after study  completion unless local regulations or 
institutional policies require a longer retention period. No records may  be destroy ed during 
the retention period without the written approval of the sponsor. No records may  be 
transferred to another location or party without written notification to the sponsor. The 
investigator must ensure that the records continue to be stored s ecurel y for aslong as they  are 
maintained.
When participant data are to be deleted, the investigator will ensure that all copi[INVESTIGATOR_78245] y deleted from all systems.
The investigator(s) will notify  the sponsor or its agents immediately  of any  regulatory  
inspection notification in relation to the study . Furthermore, the investigator will cooperate 

PF-07265803
Protocol C4411010
Final  Protocol, 26-January -2022
PFIZER CONFIDENTIAL
Page 56with the sponsor or its agents to prepare the investigator site for the inspection and will allow 
the sponsor or its agent, whenever feasible, to be present during the inspection. The 
investigator site and investigator will promptly  resolve any  discrepancies that are identified 
between the stud y data and the participant's medical records. The investigator will promptly  
provide copi[INVESTIGATOR_19946]. Before response 
submission to the regulatory  authorities, the investigator will provide the sponsor or its 
agents with an opportunity to review and comment on responses to any such findings.
10.1.8. Source Documents
Source documents provide evidence for the existence of the participant and substantiate the 
integrit y of the data collected. Source documents are filed at the investigator site.
Data reported on the CRF or entered in the eCRF that are from source documents must be 
consistent with the source documents or the discrepancies must be explained . The 
investigator may  need to request previous medical records or transfer records, depending on 
the study . Also, cur rent medical records must be available.
In this stud y, the CRF will serve as the source document. A document must be available at 
the investigative site that identifies those data that will be recorded on the CRF and for which 
the CRF will be the source do cument.
Definition of what constitutes source data and its origin can be found in Study  Monitoring 
Plan, which is maintained by  [CONTACT_456]
.
Description of the use of the computerized sy stem is documented in the Data Management 
Plan, which is maintained by [CONTACT_456].
The investigator must maintain accurate documentation (source data) that supports the 
information entered in the CRF.
Study  monitors will perform ongoing source data verification to confirm that data entered 
into the CRF by  [CONTACT_42535], complete, and verifiable from source 
documents; that the safety and rights of participants are being protected; and that the study  is 
being conducted in accordance with the currently  approved protocol and any  other study  
agreements, I CH GCP guidelines, and all applicable regulatory  requirements.
10.1.9. Study and Site Start and Closure
The study  start date is the date on which the clinical study  will be open for recruitment of 
participants.
The first act of recruitment is the date of the first participant’s first visit and will be the study  
start date.
The sponsor designee reserves the right to close the study  site or terminate the study  at any  
time for an y reason at the sole discretion of the sponsor. Study  sites will be closed upon study  

PF-[ADDRESS_496294] been collected and a stud y-site closure visit has been performed.
The investigator may  initiate study -site closure at any  time upon notification to the sponsor 
ordesignee/ CRO if requested to do so by  [CONTACT_51025] I RB/EC or if such termination is 
required to protect the health of study  participants .
Reasons for the earl y closure of a stud y site b y the sponsor may include but are not limited 
to:
Failure of the in vestigator to comply  with the protocol, the requirements of the 
IRB/EC or local health authorities, the sponsor's procedures, or the ICH GCP 
guidelines ;
Inadequate recruitment of participants by  [CONTACT_093];
Discontinuation of further study  interventi on development .
If the stud y is prematurely terminated or suspended, the sponsor shall promptly inform the 
investigators, the ECs/IRBs, the regulatory  authorities, and any  CRO (s) used in the study  of 
the reason for termination or suspension, as specified b y the applicable regulatory 
requirements. The investigator shall promptly  inform the participant and should assure 
appropriate 
participant therapy  and/or follow -up.
If thesponsor decides to terminate the study  for a reason unrelated to the safety  ofPF-
07265803, participants may  continue to receive PF -07265803 per the investigator’s 
judgement and protocol-specified safet y assessments will continue to be performed for these 
participants until the end of study  as defined in Section 4.4 . The following non-safet y - related 
study  procedures and assessments may  be stopped upon written notification from the 
sponsor:
Study  termination is also provided for in the clinical study  agreement. If there is any  conflict 
between the c ontract and this protocol ,the contract will control as to termination rights.
10.1.10. Publication Policy
The results of this study  may  be published or presented at scientific meetings b y the 
investigator after publication of the overall study  results or 1year after the end of the stud y 
(or study  termination), whichever comes first. 
The investigator agrees to refer to the primary  publication in any  subsequent publications ,
such as secondary manuscripts, and submit s all manuscripts or abstracts to the sponsor 
[ADDRESS_496295] editorial and ethical practice, the 
sponsor will support publication of multicenter studies only  in their entirety and not as 
individual site data. In this case, a coordinating investigator [INVESTIGATOR_78246].
Authorship of publications for the overall study  results will be determined by  [CONTACT_78275] I nternational Committee of Medical Journal Editors authorship 
requirements. 
If publication is addressed in the clinical study agreement, the p ublication policy  set out in 
this section will not apply.
10.1.11. Sponsor’s Qualified Medical Personnel
The contact [CONTACT_1133]'s appropriately qualified medical personnel for the 
study  is documented in the study  contact [CONTACT_394988]/study  portal or other electronic s ystem. 
To facilitate access to appropriatel y qualified medical personnel for study -related medical 
questions or problems, participants are provided with an Emergency  Contact [CONTACT_74057] (ECC) at 
the time of informed consent. The ECC contains, at a minimum, (a) protocol and study  
intervention identifiers, (b) participant’s stud y identification number, (c) site emergency 
phone number active 24 hours/day , 7 day s per week, and (d) [COMPANY_007] Call C enter number.
The ECC is intended to augment, not replace, the established communication pathway s 
between the investigator, site staff, and study  team. The ECC is to be used by  [CONTACT_78277] y only , as a means of reaching the in vestigator 
or site staff related to the care of a participant. The [COMPANY_007] Call Center number should only  be 
used when the investigator and site staff cannot be reached. The [COMPANY_007] Call Center number is 
not intended for use b y the participant directly ; if a participant calls that number directl y, he 
or she will be directed back to the investigator site.

PF-07265803
Protocol C4411010
Final  Protocol, 26-January -2022
PFIZER CONFIDENTIAL
Page 5910.2. Appendix 2: Clinical Laboratory Tests
The following safet y laboratory  tests will be performed at times defined in the SoA section of 
this protocol. Additional laboratory  results may be reported on these samples as a result of 
the method of anal ysis or the ty pe of anal yzer used by  [CONTACT_20019] ,or as derived 
from calculated values. These additional tests would not require additional collection of 
blood. Unscheduled clinical laboratory  measurements may  be obtained at any  time during the 
study  to assess an y perceived safet y issues.
Table 4. Protocol -Required Safet y Laboratory Assessments
Hem atology Chemistry Urinalysis Other
Hem oglobin
Hem atocrit
RBC count
MCV
MCH
MCHC
Platelet count
WBC count
Total neutrophils (Abs)
Eosinophils (Abs)
Monocytes (Abs)
Basophils (Abs)
Lymphocytes (Abs)BUN and creatinine
Glucose (fasting)
Calcium
Sodium
Potassium
Chloride
Total CO 2(bicarbonate)
AST, ALT
Total bilirubinc
Alkaline phosphatase
Uric acid
Albumin
Total proteinLocal Dipstick:
pH
Glucose (qual)
Protein (qual)
Blood (qual)
Ketones
Nitrites
Leukocyte esterase
Laboratory:
Microscopy and 
CultureaCOVID -19 testing
At screen ingonly:
Hepatitis B surface antigen
Hepatitis C antibody
Human immunodeficiency 
virus
At screen ingand adm ission
(check -in)only:
Urine co tinine
Urine drug screeningb
At admission (check -in)only:
Urine alcohol
a.Microscopy will be conducted if urine dipstick is positive for blood, protein, nitrites, or leukocyte esterase.
Culture only conducted if bacteriuria present upon microscopy .
b.Theminimum requirement for drug screening includes cocaine, THC, opi[INVESTIGATOR_858]/opi[INVESTIGATOR_2438], benzodiazepi[INVESTIGATOR_1651], 
and amphetamines (others are site and study specific).
c. Direct and indirect bilirubin w ill be measured if total bilirubin is elevated
The investigator must review the laboratory  report, document this review, and record any  
clinically  relevant changes occurring during the study in the AE section of the CRF.
Any remaining serum/plasma from samples collected for clinical safet y lab oratory  
measurements at baseline and at all times after dose administration may be retained and 
stored for the duration of the study . Upon completion of the study , these retained safety  
samples may  be used for the assessment of exploratory  safet y biomarkers or unexpected 
safet y findings . These data will not be included in the CSR
. Samples to be used for this 
purpose will be shipped to either a [COMPANY_007] -approved BBS facility  or other designated 
laboratory  and retained for up to 1year following the completion of th e study .

PF-07265803
Protocol C4411010
Final  Protocol, 26-January -2022
PFIZER CONFIDENTIAL
Page 6010.3. Appendix 3: Adverse Events: Definitions and Procedures for Recording, 
Evaluating, Follow -Up, and Reporting
10.3.1. Definition of AE
AE Definition
An AE is an y untoward medical occurrence in a patient or clinical study 
participant, temporall y associated with the use of study intervention, whether or not 
considered related to the study  intervention.
Note: An AE can therefore be an y unfavorable and unintended sign (including an 
abnormal laboratory  finding), s ymptom, or disease (new or exacerbated) temporally  
associated with the use of study  intervention.
Events Meeting the AE Definition
Any abnormal laboratory test results (hematology , clinical ch emistry , or urinaly sis) 
or other safet y assessments (eg, ECG, radiological scans, vital sign measurements), 
including those that worsen from baseline, considered clinicall y significant in the 
medical and scientific judgment of the investigator. Any abnorma l laboratory  test 
results that meet an y of the conditions below must be recorded as an AE:
Is associated with accompany ing s ymptoms;
Requires additional diagnostic testing or medical/surgical intervention ;
Leads to a change in study  dosing (outside of any  protocol -specified dose 
adjustments) or discontinuation from the study , significant additional 
concomitant drug treatment, or other therap y.
Exacerbation of a chronic or intermittent preexisting condition, including either an 
increase in frequency  and/or intensity  of the condition.
New condition detected or diagnosed after stud y intervention administration ,even 
though it may  have been present before the start of the study .
Signs, sy mptoms, or the clinical sequelae of a suspected drug -drug interaction.
Signs, symptoms, or the clinical sequelae of a suspected overdose of either study  
intervention or a concomitant medication. Overdose per se will not be reported as 
an AE or SAE unless it is an intentional overdose taken with possible 
suicidal/self- harming inte nt. Such overdoses should be reported regardless of 
sequelae.

PF-07265803
Protocol C4411010
Final  Protocol, 26-January -2022
PFIZER CONFIDENTIAL
Page 61Events NOT Meeting the AE Definition
Any clinically  significant abnormal laboratory  findings or other abnormal safet y 
assessments that are associated with the underl ying disease, unless judged by  [CONTACT_11009]’s condition.
The disease/disorder being studied or expected progression, signs, or s ymptoms of 
the disease/disorder being stu died, unless more severe than expected for the 
participant’s condition.
Medical or surgical procedure (eg, endoscop y, appendectom y): the condition that 
leads to the procedure is the AE.
Situations in which an untoward medical occurrence did not occur (soci al and/or 
convenience admission to a hospi[INVESTIGATOR_307]).
Anticipated day -to-day fluctuations of preexisting disease(s) or condition(s) present 
or detected at the start of the study that do not worsen.
10.3.2. Definition of an SAE
AnSAE is defined as any untoward medical occurrence that, at any dose, meets one 
or more of the criteria listed below:
a.Results in death
b.Is life -threatening
The term “life-threatening ”in the definition of “serious” refers to an event in which the 
participant was at risk of death at the time of the event. It does not refer to an event that
hypothetically  might have caused death if it were more severe.
c.Requires inpatient hospi[INVESTIGATOR_216472], hospi[INVESTIGATOR_12994] (usually  
involving at least an overnight stay ) at the hospi[INVESTIGATOR_19950]/or treatment that would not have been appropriate in the ph ysician’s office or 
outpatient setting. Complications that occur during hospi[INVESTIGATOR_1084]. If a 
complication prolongs hospi[INVESTIGATOR_9236], the event is 
serious. When in doubt as to whether “hospi[INVESTIGATOR_059]” occurred or w as necessary , the 
AE should be considered serious.
Hospi[INVESTIGATOR_5187] a preexisting condition that did not worsen 
from baseline is not considered an AE.

PF-07265803
Protocol C4411010
Final  Protocol, 26-January -2022
PFIZER CONFIDENTIAL
Page 62d.Results in persistent or significant disability/incapacity
The term disability  means a substantial disruption of a person’s ability  to conduct 
normal life functions.
This definition is not intended to include experiences of relativel y minor medical 
significance ,
such as uncomplicated headache, nausea, vomiting, diarrhea, 
influenza, and accidental trauma (eg, sprained ankle), thatmay interfere with or 
prevent every day life functions but do not constitute a substantial disruption.
e.Is a congenital anomaly/birth defect
f.Is a suspected transmission via a [COMPANY_007] product of an infectious a gent, pathogenic 
or non- pathogenic, is considered serious.  
The event may  be suspected from clinical s ymptoms or laboratory  findings indicating 
an infection in a participant exposed to a [COMPANY_007] product. The terms “suspected 
transmission” and “transmission” are considered sy nony mous. These cases are 
considered unexpected and handled as serious expedited cases b y pharmacovigilance 
personnel. Such cases are also considered for reporting as product defects, if 
appropriate.
g.Other situations:
Medic al or scientific judgment should be exercised by  [CONTACT_78278], such as significant 
medical events that may jeopardize the participant or may  require medical or 
surgical intervention t o prevent one of the other outcomes listed in the above 
definition. These events should usually  be considered serious.
Examples of such events include invasive or malignant cancers, intensive treatment 
in an emergency  room or at home for allergic bronchosp asm, blood dy scrasias or 
convulsions that do not result in hospi[INVESTIGATOR_059], or development of drug 
dependency  or drug abuse.
10.3.3. Recording/Reporting and Follow -Up of AE sand/or SAE sDuring the Active 
Collection Period
AE and SAE Recording /Reporting
The table below summarizes the requirements for recording AEs on the CRF and for 
reporting SAEs on the CT SAE Report Form to [COMPANY_007] Safet ythroughout the active 
collection period . These requirements are delineated for 3 ty pes of events: (1) SAEs; (2) 
nonse rious AEs; and (3) exposure to the study  intervention under stud y during pregnancy  
or breastfeeding, and occupational exposure. 

PF-[ADDRESS_496296] SAE 
Report Form to [COMPANY_007] 
Safety Within 24 Hours of 
Awareness
SAE All All
Nonserious AE All None
Exposure to the study  
intervention under stud y 
during pregnancy  or 
breastfeedingAll AEs/SAEs associated 
with exposure during 
pregnancy  or breastfeeding
Note:   Instances of EDP or 
EDB not associated with an 
AE or SAE are not captured 
in the CRF.All instances of EDP are 
reported (whether or not 
there is an associated 
SAE)*
All instances of EDB ar e 
reported (whether or not 
there is an associated 
SAE). **
Environmental or 
occupational exposure to 
the product under stud y 
to a non -participant (not 
involving EDP or EDB).None.  Exposure to a study  
non-participant is not 
collected on the CRF.The exposure (whether or 
not there is an associated 
AE or SAE) must be 
reported.***
*EDP (with or without an associated AE or SAE): any pregnancy information is reported to 
[COMPANY_007] Safety using CT SAE Report Form and EDP Supplemental Form; if the EDP is 
associated with an SAE, then the SAE is reported to [COMPANY_007] Safety using the CT SAE Report 
Form . 
** EDB is reported to [COMPANY_007] Safety using the CT SAE Report Form which w ould also include 
details of any SAE that might be associated w ith the EDB. 
***Environmental or Occupational exposure: AEs or SAEs associated with occupational exposure 
are reported to [COMPANY_007] Safety using the CT SAE Report Form. 
When an AE or SAE occurs, it is the responsibility  of the investigator to review all 
documentation (eg, hospi[INVESTIGATOR_1088], laboratory  reports, and diagnostic 
reports) related to the event.
The investigator will then record all relevant AE or SAE information in the CRF.
It is notacceptable for the investigator to send photocopi[INVESTIGATOR_10914]’s 

PF-[ADDRESS_496297] SAE Report 
Form /AEor SAE CRF page.
There may  be instances when copi[INVESTIGATOR_221708] b y [COMPANY_007] Safety .In this case, all participant identifiers, with the 
exception of the participant number, will be redacted on the copi[INVESTIGATOR_19953] .
The investigator will attempt to establish a diagnosis of the event based on signs, 
symptoms, and/or other clinical information. Whenever possible, the diagnosis (not 
the individual signs/sy mptoms) will be documented as the AE or SAE.
Assessment of Intensity
The investigator will make an assessment of intensity  for each AE and SAE reported 
during the stud y and assign it to 1 of the following categories: 
Mild: Asymptomatic or mild sy mptoms; clinical or diagnostic observations only ; 
intervention not indicated.
Moderate: Minimal, local or noninvasive int ervention indicated; limiting age -
appropriate instrumental ADL. Instrumental ADL refers to preparing meals, 
shoppi[INVESTIGATOR_3112], using the telephone, managing money , etc.
Severe: Severe or medically  significant but not immediately  life-threat ening; 
hospi[INVESTIGATOR_3111]; disabling, limiting self 
care ADL. Self care ADL refers to bathing, dressing and undressing, feeding self, 
using the toilet, taking medications, and not bedridden.
An event is defined as “serious” when it meets at least 1 of the predefined outcomes as 
described in the definition of an SAE, NOT when it is rated as severe.
Assessment of Causality
The investigator is obligated to assess the relationship between stud y intervention 
and each occurrence of each AE or SAE. The investigator will use clinical 
judgment to determine the relationship.
A “reasonable possibility” of a relationship conveys that there are facts, evidence, 
and/or arguments to suggest a causal relationship, rather than a r elationship cannot 
be ruled out.
Alternative causes, such as underl ying disease(s), concomitant therap y, and other 
risk factors, as well as the temporal relationship of the event to study  intervention 

PF-07265803
Protocol C4411010
Final  Protocol, 26-January -2022
PFIZER CONFIDENTIAL
Page 65administration, will be considered and investigated.
The investigator will also consult the IB and/or product information, for marketed 
products, in his/her assessment.
For each AE or SAE, the investigator must document in the medical notes that 
he/she has reviewed the AE or SAE and has provided an assessment of causality .
There may  be situations in which an SAE has occurred and the investigator has 
minimal information to include in the initial report to the sponsor. However, it is 
very important that the investigator always make an assessment of causality 
for every event before the initial transmission of the SAE data to the sponsor .
The investigator may  change his/her opi[INVESTIGATOR_19954] -up 
information and send a nSAE follow -up report with the updated causality  
assessment.
The causality  assessment is one of the criteria used when determining regulatory  
reporting requirements.
If the investigator does not know whether or not the study  intervention caused the 
event, then the event will be handled as “related to study  interventio n” for reporting 
purposes, as defined b y the sponsor . In addition, if the investigator determines that 
an SAE is associated with study  procedures, the investigator must record this causal 
relationship in the source documents and CRF, and report such an ass essment in the 
dedicated section of the CT SAE Report Form and in accordance with the SAE 
reporting requirements.
Follow -Up of AEs and SAEs
The investigator is obligated to perform or arrange for the conduct of supplemental 
measurements and/or evaluations, as medically  indicated or as requested by  [CONTACT_103] ,to elucidate the nature and/or causalit y of the AE or SAE as full y as 
possible. This may  include additional laboratory  tests or investigations, 
histopathological examinations, or consultation with other healthcare providers .
If a participant dies during p articipation in the study  or during a recognized 
follow -up period, the investigator will provide [COMPANY_007] Safet y with a cop y of any 
postmortem findings
,including histopathology .
New or updated information will be recorded in the originally  submitted 
docume nts
.
The investigator will submit any  updated SAE data to the sponsor within 24 hours 

PF-07265803
Protocol C4411010
Final  Protocol, 26-January -2022
PFIZER CONFIDENTIAL
Page 66of receipt of the information.
10.3.4. Reporting of SAEs
SAE Reporting to [COMPANY_007] Safety via an Electronic Data Collection Tool
The primary  mechanism for reporting an SAE to [COMPANY_007] Safety will be the electronic 
data collection tool.
If the electronic s ystem is unavailable, then the site will use the paper SAE data 
collection tool ( see next section) to report the event within 24 hours.
The site will enter the SAE data into the electronic sy stem as soon as the data
become available.
After the stud y is completed at a given site, the electronic data collection tool will 
be taken off -line to prevent the entry  of new data or changes to existing data.
If a site receives a report of a new SAE from a study  participant or receives updated 
data on a previously  reported SAE after the electronic data collection tool has been 
taken off -line, then the site can report this information on a paper SAE form (see 
next section) or to [COMPANY_007] Safety  by [CONTACT_756].
SAE Reporting to [COMPANY_007] Safety via CT SAE Report Form
Facsimile transmission of the CT SAE Report Form is the preferred method to 
transmit this information to [COMPANY_007] Safety .
In circumstances when the facsimile is not working , notification by  [CONTACT_20021] a cop y of the CT SAE Report Form sent by  [CONTACT_20022].
Initial notification via telephone does not replace the need for the investigator to 
complete and sign the CT SAE Report Form pages w ithin the designated reporting 
time frames.

PF-07265803
Protocol C4411010
Final  Protocol, 26-January -2022
PFIZER CONFIDENTIAL
Page 6710.4. Appendix 4: Contraceptive and Barrier Guidance
10.4.1. Male Participant Reproductive Inclusion Criteria
Male participants are eligible to participate if they  agree to the following requirements during 
the intervention period and for at least 30daysafter the last dose of stud y intervention, which 
corresponds to the time needed to eliminate reproductive safe ty risk of the study  
intervention(s) plus an additional 90 days (a spermatogenesis cy cle): 
Refrain from donating sperm.
PLUS either :
Be abstinent from heterosexual intercourse as their preferred and usual lifesty le 
(abstinent on a long -term and persisten t basis) and agree to remain abstinent ;
OR
Must agree to use contraception/barrier as detailed below :
Agree to use a male condom when engaging in any activity  that allows for 
passage of ejaculate to another person .
Use of an additional highly  effective contraceptive method with a failure rate of 
<1% per year as described below in Section 10.4.4 for a female partner of 
childbearing potential.
10.4.2. Female Participant Reproductive Inclusion Criteria
Females are not eligible to enroll in this study
10.4.3. Woman of Childbearing Potential
A woman is considered fertile following menarche and until becoming postmenopausal 
unless permanentl y sterile (see below).
If fertility  is unclear (eg, amenorrhea in adolescents or athletes) and a menstrual cy cle cannot 
be confirmed before the 
first dose of study  intervention, additional evaluation should be 
considered.
Women in the following categories are notconsidered WOCBP:
1.Premenarchal .
2.Premenopausal female with 1 of the following:
Documented h ysterectomy ;

PF-07265803
Protocol C4411010
Final  Protocol, 26-January -2022
PFIZER CONFIDENTIAL
Page 68Documented bilateral salpi[INVESTIGATOR_1656] ;
Documented bilateral oophorectom y.
For individuals with permanent infertil ity due to an alternate medical cause other than 
the above, (eg, mullerian agenesis, androgen insensitivity ), investigator discretion 
should be applied to determining study  entry .
Note: Documentation for any  of the above categories can come from the site 
personnel’s review of the participant’s medical records, medical examination, or 
medical history  interview. The method of documentation should be recorded in the 
participant’s medical record for the stud y.
3.Postmenopausal female .
A postmenopausal state is de fined as no menses for 12 months without an 
alternative medical cause. In addition :
A high FSH level in the postmenopausal range must be used to confirm a 
postmenopausal state in women under 60 years old and 
not using hormonal 
contraception or HRT. 
A female on HRT and whose menopausal status is in doubt will be required to 
use one of the nonestrogen hormonal highly effective contraception methods 
if they  wish to continue their HRT during the study .Otherwise, they  must 
discontinue HRT to allow confirmation of postmenopausal status before study  
enrollment.
10.4.4. Contracepti onMethods
Contraceptive use b y men or women should be consistent with local availability /regulations 
regarding the use of contraceptive methods for those participating in clinical trials.
Highly Effective Methods That Have Low User Dependen cy
1.Implantable progestogen -only hormone contraception associated with inhibition of 
ovulation.
2.Intrauterine device .
3.Intrauterine hormone -releasing s ystem.
4.Bilateral tubal occlusion (eg, bilateral tubal ligation) .

PF-07265803
Protocol C4411010
Final  Protocol, 26-January -2022
PFIZER CONFIDENTIAL
Page 695.Vasectomized partner .
A vasectomized partner is a highl y effective contraceptive method provided that 
the partner is the sole sexual partner of the WOCBP and the absence of sperm has 
been confirmed. If not, an additional highl y effective method of contraception 
should be used. The s permatogenesis cy cle is approximately  90days.
Highly Effective Methods That Are User Dependent
6.Combined (estrogen- and progestogen -containing) hormonal contraception associated 
with inhibition of ovulation .
Oral;
Intravaginal;
Transdermal ;
7.Progestogen -only hormone contraception associated with inhibition of ovulation .
Oral;
Injectable .
8.Sexual abstinence .
Sexual abstinence is considered a highl y effective method only  if def ined as 
refraining from heterosexual intercourse during the entire period of risk associated 
with the study  intervention. The reliability  of sexual abstinence needs to be 
evaluated in relation to the duration of the stud y and the preferred and usual 
lifest yle of the participant.
One of the following effective barrier methods must be used in addition to the highl y 
effective methods listed above that are user dependent:
Male or female condom with or without spermicide;
Cervical cap, diaphragm, or sponge with spermicide ;
A combination of male condom with either cervical cap, diaphragm, or sponge with 
spermicide (double -barrier methods) .

PF-07265803
Protocol C4411010
Final  Protocol, 26-January -2022
PFIZER CONFIDENTIAL
Page 7010.5. Appendix 5: Genetics
Genetics (specified anal yses) are not evaluated in this study .

PF-07265803
Protocol C4411010
Final  Protocol, 26-January -2022
PFIZER CONFIDENTIAL
Page 7110.6. Appendix 6: Liver Safety: Suggested Actions and Follow-U p Assessments 
Potential Cases of Drug- Induced Liver Injury
Humans exposed to a drug who show no sign of liver injury  (as determined by  [CONTACT_20023]) are termed “tolerators,” while those who show transie nt liver injury  but adapt 
are termed “adaptors.” In some participant s, transaminase elevations are a harbinger of a 
more serious potential outcome. These participant s fail to adapt and therefore are 
"susceptible" to progressive and serious liver injury, co mmonl y referred to as DILI.  
Participant s who experience a transaminase elevation above 3 ×ULN should be monitored 
more frequently  to determine if they  are “adaptor s” or are “susceptible.”
LFTs are not required as a routine safety  monitoring procedure in this study . However, 
should an investigator deem it necessary  to assess LFTs because a participant presents with 
clinical signs/s ymptoms, such LFT results should be managed and followed as described 
below.
In the majority  of DILI cases, elevations in AST and/or ALT precede TBili elevations 
(>2×ULN) b y several day s or weeks. The increase in TBili ty pi[INVESTIGATOR_216474]/ALT 
is/are still elevated above 3 ×ULN (ie, AST/ALT and TBili values wil
l be elevated within 
the same lab oratory sample). In rare instances, by [CONTACT_22858], 
AST/AL T values might have decreased. This occurrence is still regarded as a potential DILI.  
Therefore, abnormal elevations in either AST OR ALT in addition to TBili that meet the 
criteria outlined below are considered potential DILI (assessed per Hy ’s law criteria) cases
and should alway s be considered important medical events, even before all other possible 
causes of liver injury  have been exclu ded.
The threshold of laboratory  abnormalities for a potential DILI case depends on the 
participant ’s individual baseline values and underly ing conditions. Participant s who present 
with the following laboratory  abnormalities should be evaluated further as potential DILI 
(Hy’s law) cases to definitively  determine the etiology  of the abnormal laboratory  values:
Participant s with AST/ALT and TBili baseline values within the normal range who 
subsequently  present with AST OR AL T values >3 ×ULN AND a TBili value
>2× ULN with no evidence of hemol ysis and an alkaline phosphatase value 
<2×ULN or not available.
For participant s with baseline AST OR ALT ORTBili values above the ULN, the 
following threshold values are used in the definition mentioned above, as need ed, 
depending on which values are above the ULN at baseline:
Preexisting AST or ALT baseline values above the normal range: AST or ALT 
values >2 times the baseline values AND >3 ×ULN; or >8 ×ULN (whichever is 
smaller).

PF-07265803
Protocol C4411010
Final  Protocol, 26-January -2022
PFIZER CONFIDENTIAL
Page 72Preexisting values of TBili above the normal range: TBili level increased from 
baseline value b y an amount of at least 1 × ULN orif the value reaches 
>3×ULN (whichever is smaller).
Rises in AST/AL T and TBili separated b y more than a few weeks should be assessed 
individually  based on clin ical judgment; an y case where uncertainty  remains as to whether it 
represents a potential Hy’s law case should be reviewed with the sponsor. 
The participant should return to the investigator site and be evaluated as soon as possible, 
preferabl y within [ADDRESS_496298] and AL T and TBili for suspected Hy ’s law 
cases , additional laboratory  tests should include albumin, CK, direct and indirect bilirubin, 
GGT, PT/INR, total bile acids, and alkaline phosphatase. Consideration should also be given 
to drawing a separate tube of clotted blood and an anticoagulated tube of blood for further 
testing, as needed, for further contemporaneous analy ses at the time of the recognized initial 
abnormalities to determine etiology . A detailed history , including rel evant information, such 
as review of ethanol, acetaminophen /paracetamol (either by  [CONTACT_20025] a coformulated 
product in prescription or over -the-counter medications) , recreational drug, or supplement 
(herbal) use and consumption, family  history
, sexual h istory , travel history, history  of contact 
[CONTACT_4490] a jaundiced person, surgery , blood transfusion, history  of liver or allergic disease, and 
potential occupational exposure to chemicals, should be collected. Further testing for acute 
hepatitis A, B, C, D, and E infection ,liver imaging (eg, biliary  tract) ,and collection of serum 
sample s for acetaminophen/paracetamol drug and/or protein adduct levels may be warranted. 
All cases demonstrated on repeat testing as meeting the laboratory  criteria of AST/AL T and 
TBili elevation defined above should be considered potential DILI (Hy ’s law) cases if no 
other reason for the LFT abnormalities has yet been found. Such potential DILI (Hy’s law) 
cases are to be reported as SAEs, irrespective of availability of all the resu lts of the 
investigations performed to determine etiology of the LFT abnormalities.
A potential DILI (Hy ’s law) case becomes a confirmed case onl y after all results of 
reasonable investigations have been received and have excluded an alternative etiology .

PF-07265803
Protocol C4411010
Final  Protocol, 26-January -2022
PFIZER CONFIDENTIAL
Page 7310.7. Appendix 7: ECG Findings of Potential Clinical Concern
ECG Findings T hat May Q ualify as AEs
Marked sinus bradycardia (rate <40 bpm) lasting minutes.
New PR interval prolongation >280 ms ec.
New prolongation of QTcF to >480 ms ec(absolute) or by60msecfrom baseline .
New -onset atrial flutter or fibrillation, with controlled ventricular response rate: ie, 
rate<120 bpm .
New -
onset typeI second - degree (Wenckebach) AV block of >30 seconds’ duration.
Frequent PVCs, triplets , orshort intervals (<30 seconds) of consecutive ventricular 
complexes .
ECG Findings T hat May Q ualify as SAEs
QTcF prolongation >500 ms ec.
New ST- T changes suggestive of my ocardial ischemia .
New -onset l eft bundle branch block (QRS >120 msec).
New -onset right bundle b ranch block (QRS >120 ms ec).
Symptomatic bradycardia .
Asystole:
In awake, s ymptom -free participant s in sinus rhy thm, with documented periods 
of as ystole ≥3.0 seconds or an y escape rate <40 bpm, or with an escape rhy thm 
that is below the AV node. 
In awake, s ymptom -free participant s with atrial fibrillation and brad ycardia 
with [ADDRESS_496299] 5 seconds or longer. 
Atrial f lutter or fibrillation, with rapid ventricular response rate: rapid = rate 
>120 bpm.
Sustained s upraventricular tachycardia (rate >12 0bpm) (“sustained ”= short 
duration with relevant symptoms or lasting >1 minute) .
Ventricular r hythms >30 seconds’ duration, including idioventricular rhy thm ( heart 
rate <40 bpm), accelerated idioventricular rh ythm (HR > 40bpm to <100 bpm),and 

PF-07265803
Protocol C4411010
Final  Protocol, 26-January -2022
PFIZER CONFIDENTIAL
Page 74monomorphic/poly morphic ventricular tach ycardia (HR >100 bpm (such as
torsades de pointes) ).
Type IIsecond -degree (Mobitz II)AVblock.
Complete (third
-degree) heart block.
ECG Findings T hat Q ualify as SAEs
Change in pattern suggestive of new myocardial infarction .
Sustained ventricular t achy arrhy thmias (>30 seconds ’duration) .
Second- or third -degree AV block requiring pacemaker placement.
Asystolic pauses requiring pacemaker placement.
Atrial flutter or fibrillation with rapid ventricular re sponse requiring cardioversion
.
Ventricular fibrillation/ flutter .
At the discretion of the investigator, an y arrh ythmia classified as an adverse 
experience .
The enumerated list of major events of potential clinical concern are recommended as “alerts ”or 
notifications from the core ECG lab oratory to the investigator and [COMPANY_007] study team ,and not to be 
considered as all inclusive of what to be reported as AEs/SAEs.

PF-07265803
Protocol C4411010
Final  Protocol, 26-January -2022
PFIZER CONFIDENTIAL
Page 7510.8. Appendix 8: Prohibited Concomitant Medications That May Result in DDI  
Concomitant 
medications are not allowed in this study
10.9. Appendix 9: Abbreviations
The following is a list of abbreviations that may  be used in the protocol.
Abbreviation Term
6MWT six minute walk time distance
Abs absolute
ADE adverse device effect
ADL activities of daily living
ADME absorption , distribution, metabolism, excretion
AE adverse event
AESI adverse events of special interest
ALARA as low as reasonabl y achievable
ALT alanine aminotransferase
API [INVESTIGATOR_394980] -time curve from time zero to infinity
AUC last area under the  concentration -time curve from zero to time of last 
measurable concentration
AV atrioventricular
BA bioavailability
BBS Biospecimen Banking S ystem
BE bioequivalence
BID twice -a-day
BMI body  mass index
BP blood pressure
bpm beats per minute
BUN blood urea nitrogen
CFR Code of Federal Regulations
CIOMS Council for International Organizations of Medical Sciences
CK creatine kinase
Clast last observable concentration
CL/F Apparent clearance of drug from e.g.,plasma, for extravascular 
routes of administration
Cmax maximum observed concentration
CO 2 carbon dioxide (bicarbonate)
COVID -[ADDRESS_496300] clinical trial ; computed tomograph y
CYP cytochrome P450
DDI drug-drug interaction 
DILI drug-induced liver injury
DMC Data Monitoring Committee
DMD Duchenne muscular d ystrophy
DNA deox yribonucleic acid
DU dispensable unit
EC ethics committee
ECC emergency  contact [CONTACT_394989] -Dreifuss Muscular Dy strophy
EDP exposure during pregnancy
EDR extemporaneous dispensing record
EMA European Medicines Agency
EU European Union
EudraCT European Clinical Trials Database
FDA Food and Drug Administration
FMO flavin monooxoy genase
FSH follicle -stimulating hormone
GCP Good Clinical Practice
GGT gamma -glutamy l transferase
GI gastrointestinal
GMP Good Manufacturing Practice
HBsAg hepatitis B surface antigen
HCVAb hepatitis C antibody
HIV human immunodeficiency virus
HR heart rate
HRT hormone replacement therap y
HSP28 heat shock protein 28
IB Investigator’s Brochure
IBS irritable bowel s yndrome
IC50 concentration corresponding to 50% inhibition
ICD informed consent document
ICH International Council for Harmonisation of Technical Requirements 

PF-[ADDRESS_496301]
Loge natural logarithm
LVEF left ventricular ejection fraction
MAPK mitogen -activated protein kinase
MCH mean corpuscular hemoglobin
MCHC mean corpuscular hemoglobin concentration
MCV mean corpuscular volume
msec millisecond
N/A not applicable
NT-proBNP N-terminal pro b -type natriuretic peptide
p38α MAPK p38-alpha mitogen activated protein kinase
PCR polymerase chain reaction
PD pharmacod ynamic(s)
P-gp P-glycoprotein
PI [INVESTIGATOR_19959](s)
PO oral
PT prothrombin time
PVC premature ventricular contraction/complex
QD once dail y
QTc corrected QT
QTcF corrected QT (Fridericia method)
QTL quality  tolerance limit
qual qualitative
RNA ribonucleic acid
RV right ventricular
SADE serious adverse device effect
SAE serious adverse event
SAP Statistical Analysis Plan

PF-[ADDRESS_496302] operating procedure
SRSD single reference safet y document
S[LOCATION_003]R suspected unexpected serious adverse reaction
TBili total bilirubin
THC tetrah ydrocannabinol
Tmax time of maximum observed concentration
t1/[ADDRESS_496303]
Vz/F Apparent volume of distribution, estimated from terminal phase, for 
extravascular dosing
WBC white blood cell
WOCBP woman /women of childbearing potential

PF-07265803
Protocol C4411010
Final  Protocol, 26-January -2022
PFIZER CONFIDENTIAL
Page 7911.REFERENCES
1. Fatkin D, MacRae C, Sasaki T et al. Missense mutations in the rod domain of the lamin 
A/C gene as causes of dilated cardiomy opathy  and conduction- system disease. N Engl J 
Med.1999;341(23):1715 -24.
2. Penner N, Klunk L, Prakash C. Human Radiolabeled m ass balance studies: objectives, 
otilities and l imitations . Biopharm Drug Dispos. 2009;30:185–203.
